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This work demonstrates the application of Bio-Micro Electro Mechanical System 
(Bio-MEMS) technology for early breast cancer detection and diagnosis.  Early breast cancer 
detection and diagnosis typically uses conventional mammogram screening followed by 
biopsy, which can be problematic since mammography can only detect highly calcified 
tumors greater than 1 cm in size.  A micro-device was developed to identify and specifically 
collect tumor cells of low abundance (1 tumor cell among 107 normal blood cells) from 
circulating whole blood.   
By immobilizing anti-EpCAM (Epithelial Cell Adhesion Molecule) antibodies on 
polymer micro-channel walls by the chemical surface modification of PMMA, breast cancer 
cells from the cell line MCF-7, which over-express EpCAM on their surfaces, were caught by 
the strong binding affinity between the antibody and antigen.  
To validate the capture of the rare breast cancer cells, three fluorescence markers, each 
identified by a separate color, were used to reliably distinguish the cancer cells from blood 
cells.  The cancer cells were defined by DAPI+ (blue), CD45-and the FITC-cell membrane 
linker+ (green). White blood cells, which will interfere in the detection of the cancer cells, 
were identified by DAPI+ (blue), CD45+ (red), and the FITC-cell membrane linker+ (green).  
Three EpCAM/Anti-EpCAM binding models were used to determine an optimal 
velocity, 2mm/sec, which should guarantee the binding of the maximum number of cells, a 
critical binding force, and a maximum throughput. At higher velocities, shear forces (> 0.48 
dyne) will break existing bonds and prevent formation of new ones. This detection micro-
xii 
device can be assembled with other lab-on-a-chip components for follow- up gene and protein 
marker analysis. 
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Chapter 1      Introduction 
1.1 The Importance of Early Detection of Breast Cancer 
Breast cancer, the most common cancer in women, represents the second leading 
cause of death in women in the United States after lung cancer. Each year invasive breast 
cancer is diagnosed in 180,000 women in the US, and more than 40,000 women die from 
this disease (Patlak, 2001). The occurrence rate of breast cancers in females varies with 
geography, with the highest frequency of 1 in 4 female cancers in North America and 
Western Europe, to a low frequency of 1 in 16 in China and Japan (Patlak, 2001).  
Before researchers discover new therapies to prevent breast cancer and cure all women 
patients at any stage of cancer, early cancer detection will be looked upon as the most 
effective strategy for reducing the burden of this disease. In clinical trials to reduce breast 
cancer death, some patient cases have shown that the successes of the breast cancer 
treatments are, as with most cancers, highly dependent on early detection of tumor 
formation. Treatment in the earlier ages, corresponding to the earlier detection of tumors, is 
more likely to be effective. Since female patients at early stages of tumor growth and 
proliferation can be cured when treated properly, earlier detection of tumors holds a 
wonderful hope for those people. Early cancer detection is the hallmark of successful cancer 
treatment. 
1.2 Conventional Early Breast Cancer Detection  
The widespread introduction of national screening programs for breast cancer had led 
to a significant increase in the number of non-palpable breast lesions detected (Frachebound, 
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1998). Studies have shown that routine mammography screening can reduce the number of 
deaths from breast cancer by about 25-30% among women between the ages of 50 and 70 
(Frachebound, 1998). 
 X-ray mammography and ultrasound imaging, commonly used as screening 
techniques have played important roles in breast cancer detection. Mammography imaging 
is based on density of the tissues while ultrasonic imaging is based on the acoustic 
impedance, which is the product of the density of the observed tissue and the velocity of the 
ultrasound through the tissue. The different principles underlying those two detection 
technologies, lead to mammography being used more in mass detection while ultrasound is a 
useful adjunct to mammography and used to determine if the detected abnormalities are 
benign or malignant.  
Although the diagnosis and treatment of breast cancers have noticeably improved the 
outcome of the disease, reducing the death rate over the last decade, they are not perfect due 
to the low detection rate. These screening techniques cannot eliminate all deaths from breast 
cancer because they can only detect highly calcified tumors that are ~1 mm in size. As many 
as 15% percent of breast cancers may be missed by mammography screening (Patlak, 2001). 
For the case of lung tumors, by the time tumors were noticeable by x-ray screening, 
they had already advanced to a stage that was incurable by spreading beyond the lung. 
Despite of the effectiveness of detecting small tumors by screening device, it still may not 
detect the early cancer reliably enough to reduce the number of cancer deaths. 
There are two key requirements needed to improve screening tools: sensitivity, which 
is identification, as correctly as possible, women who have breast cancer; and specificity, 
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which is to determine the type of the cancer, and how far it has spread. So far, no single 
imaging method has both high sensitivity and specificity for breast cancer (Moore, 2001). 
In addition, breast imaging techniques still need advances in image quality. 
Interpretation of mammogram images is subjective and can be variable among radiologists. 
The sensitivity of screening mammography is especially low in younger women because of 
their higher dense breast tissue (Harris, 1997). The dense tissue interferes with identification 
of abnormalities associated with tumors, which will lead to a higher rate of false test results 
in young women.   
Mammogram screening yields inconclusive results, which can require patients to 
undergo other invasive, expensive, and discomforting follow-up programs, such as the 
surgical biopsy, in which patients have to go through an operation to remove tissue samples 
from the suspicious area of the breast. Those following programs probably bring out the 
deleterious effect for some women patients, for example, due to suspicious but insufficient 
mammogram, three quarters of all breast lesions biopsied turn out to be benign, which 
means those lesions may never develop into life-threatening diseases. 
Another reason to explain the remaining breast cancer mortality despite considerable 
progress in earlier detection using these screening techniques is the intrinsic metastatic 
properties of cancer.  Conventional tumor screening and staging usually miss subsequent 
metastasis formation, which is generated with the spread of tumor cells to other sites in 
patient’s body. Due to this reason, using mammography to detect the tumors in one organ, 
while missing the target in other sites of the body will never help researchers find a way to 
treat the cancer entirely. The critical direction for cancer research should be focused on the 
cellular level cancer, and how and why these genetic errors occur. 
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1.3 Conventional Early Breast Cancer Diagnosis 
Mammogram screening is followed by surgical biopsy due to the inconclusive results. 
Suspicious tissue is removed and sent to a pathology laboratory for analysis to determine if 
the detected tumor is benign or malignant.  Fine Needle Aspiration (FNA) and Core Needle 
Biopsy (CNB), as well as surgical biopsy, are used increasingly as the initial diagnostic 
procedures. 
Some types of cancer, like pancreatic carcinomas, cannot be detected until they are far 
advanced and have invaded neighboring tissues due to their remote anatomical location. 
However, the breast is anatomically accessible; hence FNA and CNB are used increasingly 
as the initial breast cancer diagnostic procedures, as well as surgical biopsy.  
1.3.1 Fine Needle Aspiration (FNA) 
Fine needle aspiration (FNA) is a percutaneous (“through the skin”) procedure that 
uses a fine gauge needle (22 or 25 gauge) and a syringe to draw sample fluid from a breast 
cyst or remove clusters of cells from a solid mass (Meunier, 2002). The cellular material 
drawn out with FNA is sent to the pathology laboratory for analysis. There are two ways to 
perform FNA, depending on the symptoms. For the first case, if the radiologist or surgeon 
can feel a breast lump by touch, the needle will be guided into that area of concern by 
palpating (feeling) the lump. In the second case, the lump is non palpable, image guidance 
using either mammography or ultrasound is used to accomplish the FNA operation.  
By placing the needle on the region of the lesion (abnormality) to create vacuum, the 
tissue sample is taken out. If the fluid sample extracted from the breast lump appears to be 
bloody, it indicates cancer and is sent to pathology laboratory for analysis. In most case, 
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these fluids turn out to be clear, green, white, or yellow, which means that it is typically 
benign (non-cancerous), and will be simply discarded because there is no medical value 
gained from further microscopic observation and analysis. According to the breast tissue 
sample properties, the National Cancer Institute has recommended a standardized uniform 
terminology to define five categories, unsatisfactory, benign, indeterminate/atypical, 
suspicious/probably malignant, and malignant (NCI, 1997).   
As the fastest and easiest method of breast biopsy, FNA is also the simple procedure 
for patients to go through due to the fact that no stitches are required and the patients are 
capable of resuming normal routine immediately afterwards. However, FNA has the 
disadvantage of incomplete assessment because the small sample volume extracted cannot 
be evaluated in relation to the surrounding tissue. For example, based on a FNA breast 
sample, a pathologist may diagnose ductal carcinoma in situ (DCIS), a non-invasive breast 
cancer, but failed to notice infiltrating ductal carcinoma (IDC), an invasive and more lethal 
breast cancer, in a near area (Meunier, 2002).  
1.3.2 Core Needle Biospy (CNB) 
A core needle biopsy is another percutaneous (“through the skin”) procedure that 
involves removing small samples of breast tissue using a hollow “core” needle (with the 
gauge of 16, 14, or11) instead of the finer gauge needle used in FNA (Smyczek-Gargya, 
2002). To guarantee that a sufficient sample of breast tissue is obtained, three to six separate 
core needle insertions are usually needed. As with FNA, the radiologist or surgeon performs 
the procedure either by palpation or through image-guidance using mammography or 
ultrasound. Core needle biopsy (CNB) allows for a more accurate assessment of breast mass 
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than fine needle aspiration (FNA) because a larger tissue sample is removed for diagnosis. 
Nevertheless, it is still uncertain that no serious target is missed because CNB can only 
remove samples of a mass and not the entire area of concern.  
Although breast cancer is anatomically accessible using biopsy procedures, due to the 
fact that breast cancers metastasize in a very early stage, so far these biopsy procedures are 
not perfect enough to detect all cancerous tumors without error, so there is still a need for 
improved diagnostic techniques for breast cancer. 
The National Academy of Science concluded that there is a long way to go until 
cancer can be cured. A great deal of work remains to be done, particularly in the field of 
cancer protein and gene markers. This area holds promise for improving the accuracy of 
early breast cancer detection and diagnosis (Patlak, 2001).  
1.4 Gene and Protein Markers for Cancer Diagnosis 
The major objective of breast cancer research is to identify molecular changes in the 
breast tissue at an early stage. The key to really and entirely beat the breast cancer is to 
exactly understand the intrinsic nature and causes of cancer, and therefore come up with the 
effective therapies to control breast cancer at a molecular level. With the knowledge of both 
specific genes that trigger other mutations in the gene sequence, and lead to development 
chain of cancer, and characteristic cell-surface proteins referred to as tumor-associated 
antigens specific to breast cancer cells, researchers can trace down the original cause of the 
breast cancer more easily and propose effective ways to target them at the molecular level. 
Recently, significant research work has been focused on those gene and protein markers 
associated with breast cancer. 
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1.4.1 Gene Markers 
Many cancers, including breast cancer, are suspected of demonstrating chromosomal 
instability because the multiple mutations in tumor suppressor genes or photo-oncogenes 
inevitably result in uncontrolled cell growth and metastatic spread (Sidransky, 1992). Breast 
cancer is a sophisticated disease in which several genetic aberrations occur., Known 
molecular markers that are particularly important in diagnosing this disease are: BRCA-1, 
BRCA-2, p53, erbB oncogenes, loss of heterozygosity (LOH), chromosomal aberrations, 
microsatellite instability, transforming growth factor alpha (TGFα), and the multiple drug 
resistance (MDR) gene (Dahiya, 1998). The BRCA-1 and BRCA-2 genes, tumor suppressor 
genes, are identified as defects associated with family inheritance and dramatically increase 
a woman’s risk of developing breast or ovarian cancer. The knowledge of these genetic 
changes and the biological consequences related to breast cancer is critical to understand the 
cause of this disease and help to propose the rational therapy to prevent and treat it. 
Over the last few years, numerous techniques have been developed to detect mutations 
and determine the possible roles each gene marker plays in the formation of malignant 
tumors. In the work of designing an assay to analyze mutations, several tremendously 
important factors need be considered, such as inexpensive cost, high selectivity, sensitivity 
sufficient to detect the small amount of mutant DNA among a myriad of normal DNAs, 
capability of interferences prevention from the sample matrix. One of the potential 
techniques for analyzing gene mutations uses micro-electrophoretic systems for size-
fractionating DNAs (Effenhauser, 1994, Simpson, 1998), which offers high speed of 
analysis and high throughput if done in a multi-channel format. The effectiveness of this 
system is highly dependent on the length of the channel. However, building a long column 
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on a small footprint is hard to implement. An attractive alternative technique to 
electrophoretic-based genetic screening are DNA microarrays, which consist of tethered 
oligonucleotides or genomes attached to planar surfaces (Collins, 1999). Two methods 
utilized to accomplish the immobilization oligonucleotide or DNA targets on solid supports 
are the light-generated synthesis method (Pease, 1994), and inkjet technology (Guo, 1994). 
In most cases, glass is used to act as the support material for high-density micro-arrays. In 
direct to BRCA-1 gene, high-density hybridization arrays have been constructed for 
screening the entire coding region for all possible homozygous and heterozygous sequence 
changes (Hacia, 1996). Although microarrays have an intrinsic advantage, they have 
inevitable limitations as well. It is difficult to detect frameshift mutations using arrays and 
they can also be expensive to manufacture.  
1.4.2 Protein Markers 
At the early stages of tumor development, genetic markers in some cases cannot 
entirely and accurately identify a specific phenotype due to the static nature of the cell’s 
genome. For this reason, it is desirable to look at protein markers, which are specifically 
associated with breast cancer as well as the gene markers. To identify tumor cells, these 
protein markers must be either under-expressed or, more preferably. over-expressed in the 
tumor compared to the surrounding normal cells. Several tumor protein markers have been 
used increasingly in recent years as clinical tools for breast cancer diagnosis. Those typical 
protein markers include, MUC-1 (CA 15.3), Her2/neu, carcinoembryonic antigen (CEA), 
tissue polypeptide antigen (TPA), Epidermal growth factor receptor (EGFR), and epithelial 
adhesion molecule (EpCAM).  
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Her2/neu is a type I membrane protein and has been discovered to be shed in to serum 
by proteolysis of the tumor cell membrane (Slamon, 1987). Unfortunately, only 20-30% of 
breast cancer patients over-express this protein.  
Carcinoembryonic antigen (CEA), another marker for breast cancer, belongs to a 
family of cell-surface glycoproteins with increased expression in breast cancer. 
CA15-3, a high molecular weight (300 - 450 kDa) polymorphic epithelial mucin, has 
been given considerable attention as a breast tumor marker. It has been proven that CA15-3 
antigen is a more sensitive and specific indicator than Carcinoemberyonic antigen (CEA) 
(Vizarra, 1994).  
For screening protein expression, two-dimensional gel electrophoresis is commonly 
used to isolate particular protein types (Alaiya, 2000). This technique involves separating 
proteins in the first axis according to charge with isoelectric focusing (IEF), followed by 
separations of the focused proteins along the second axis by molecular weight determination 
by sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE). The proteins can be 
visualized by staining with Coomassie Brilliant Blue R250, silver stain, or fluorescent dyes 
(Gorg, 2000). While being a core technology in protein analysis for several years, 2-D 
electrophoresis is fraught with difficulties, such as a basic pH limit, long analysis time, and 
irreproducibility. 
An innovative alternate method for protein expression analysis use protein 
microarrays. These arrays are formed by printing the proteins onto activated glass surfaces. 
Then the proteins stained with fluorescence interact via molecular associations with their 
appropriate counterparts. Cancer research has utilized this technique to obtain molecular 
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profiles of human cancers for categorizing tumor cells (Liotta, 2000). In the case of breast 
cancer, several biosensors have been introduced for monitoring different markers. For 
example, Wang (Wang, 2001) developed a silicon-based ultrasonic immunosensor for the 
detection of CA15.3 antigens expressed by breast cancers. In his work, CA15.3 antibodies 
were immobilized on the surface of sensor, and once the antibody is associated with CA15.3 
by binding reaction, a mass increase resulted.  
1.5 Immunotherapy 
Antibodies have been widely used in scientific studies of cancer and cancer diagnosis 
as well. Monoclonal antibodies have been designed to recognize specific types of cancer 
cells expressing particular antigens. This strategy has appeared and been successful since the 
invention of antibodies in the 1970s. The development of monoclonal antibodies (mAbs) 
directed against epithelial differentiation antigens such as cytokeratins (CKs) and against 
tumor-associated cell-membrane glycoproteins has opened a diagnostic window to detect 
disseminated tumor cells as early as primary diagnosis (Schlimok, 1987).  
Immunotherapy is a major consideration in cancer therapy, which involves using 
antibodies against cancer cells or cancer-associated targets. The main goal of 
immunotherapy is that antibodies can be injected into patients to sieve out the cancer cells, 
potentially disrupt the cancer cell activities and enhance the immune response against the 
cancer.  
For treatment of certain breast cancers, numerous clinical tests have shown that the 
antibody trastuzumab (Herceptin) can be useful for the women whose breast cancer cells 
over-express the HER2/neu protein. Another study (Braun, 1999a) was conducted in ten 
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patients with advanced breast cancer. They received a single dose of 500 mg of 
edrecolomab, which is directed against the epithelial cell adhesion molecule (EpCAM) 
widely expressed on the surfaces of breast cancer cells (Braun, 1999a). Among all of the 
patients, a phenomenal reduction of the tumor load was monitored by a second follow-up 
bone marrow aspiration within 5-7 days of edrecolomab antibody treatment. In four of the 
ten patients, no metastatic cells could be indentified after treatment with edrecolomab. 
Therefore, it could be speculated that the observed disappearance of tumor cells from bone 
marrow was a consequence of the action of the mAbs (Braun, 2001). 
However, immunocytochemical analysis and treatment has its limitations. The actual 
target cells, like tumor cells disseminated to bone marrow, may express a heterogeneous 
pattern of the potential target antigens. Tumor antigen heterogeneity may therefore represent 
an important limitation of the efficacy of monospecific antibody therapy (Braun, 1999b). 
Also, monoclonal antibodies may have a negative effect on normal body cells, and cause 
many side effects, like high body temperature, trauma, and low blood pressure. 
1.6 Bio-MEMs 
Biological Micro-Electro-Mechanical Systems (BioMEMS) has been a topic of 
growing interest over the past decade. The fabrication of micro-instrumentation using 
photolithographic techniques has been integrated into molecular biology and offeres many 
advantages over conventional large-scale analysis tools including: reduced analysis time and 
reagent amount, and increased parallelism of analysis. Due to the small size of the micro-
devices, Bio-MEMS also have the potential to be multiplexed easily. Using fabrication 
techniques, lithographic or molding procedures, many sample processing fluidic networks 
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can be machined into the device with high packing densities. Another important and 
appealing advantage is that individual micro-components can be assembled into the device 
having specific functions. For example, with the combination of assembly and micro 
machining, various components, such as reaction and detection chambers, micro-pumps, 
micro-needles, and separation channels, can be fabricated and packed directly onto the 
instrument platform. 
Since emerging in the early 1990s, Bio-MEMS technology has now already been 
available to fabricate micro-sized mechanical parts, used in the disciplines, like biology and 
medicine. Harrison and Manz pioneered fabrication of micro-electrophoresis devices in 
glass substrates using photolithography and wet chemical etching (Harrison, 1992). After 
this profound contribution, various micro-devices have been constructed and widely used in 
bioanalytical applications, such as PCR amplification of oligonucleotides used in genomic 
applications (Cheng, 1996; Belgrader, 2001). Also, the analysis of proteins using either 
electrophoretic separation (Liu, 2000) or immunological events (Sata, 2000) have been 
reported. 
Due to the optical properties of glass or quartz substrates, all the devices mentioned 
above were built on them using photolithographic procedures and wet chemical etching. 
Also, glass substrates allow chemical modification when necessary. However, when 
considered for machining high aspect ratio features, it is difficult to fabricate channels that 
are narrow with large depth using wet etching in glass since it is an isotropic etching 
process. To solve the potential problems inherent with glass-based devices, the fabrication 
of micro-devices in plastic materials instead of glass has been initiated, such as poly 
(methylmethacrylate) (PMMA) (Martynova, 1997). An attractive property of transparent 
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polymer is that they can be easily molded into desired shapes with very high resolution 
using techniques, such as injection molding, imprinting, hot embossing, laser ablation, or X-
ray lithography. Based on the properties of different plastics, like the range of glass 
transition temperature and thermal conductivity, the right material can be selected for the 
appropriate system. For example, polycarbonate was selected as the material for PCR due to 
the high glass transition temperature required for 95°C denaturation zone.  
BioMEMS can be also widely applied in Tissue Engineering, drug delivery, 
management of diabetes, and Bio-MEMS may have many, as yet, unimagined approaches, 
and no one can predict exactly how widely and effectively this technology will be applied in 
medical field in time. 
1.7 Goal of the Project 
This work demonstrates the application Bio-MEMS technology for breast cancer 
detection and diagnosis.  Early breast cancer detection and diagnosis typically uses 
conventional mammogram screening followed by biopsy, which can be problematic due to 
the fact that mammography can only detect highly calcified tumors greater than 1 cm in size.  
A micro-device was developed to identify and specifically collect tumor cells of low 
abundance (1 tumor cell among 107 normal blood cells) from circulating whole blood.  
There were four main objectives set forth for the research. The successful completion 
of these four goals will aid in the early cancer detection and treatment: 
1. Develop a bio-micro-device using micro-fabrication technology and surface 
chemistry modification to capture tumor cells of low abundance from whole 
blood. High target cell capture efficiency of this micro-device was the ultimate 
goal; 
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2. Visualize the capture of the breast cancer cells and differentiate the target cancer 
cells from other blood cells in the micro-device; 
3. Determine an optimal velocity, which should guarantee the maximum binding of 
cancer cells, the critical dissociation force and  a maximum throughput; 
4. Apply a correct blood flow model to estimate the required pressure drops in 
micro-devices with different types of geometries. 
  
The vision of the complete assembled lab-on-a-chip system would be: a skin patch 
containing a micro-needle array to draw blood from breast tissue of the patients is put in the 
bottom of the device; next, the drawn blood flows into the micro-channels designed in this 
research, the cancer cells trapped on the wall of micro-channels are lysed and sent to PCR 
(Polymerase Chain Reaction) and other specific assay components to perform the genetic 
analysis and identification.  Each module can be a single use device.  The whole objective is 
to detect early stage breast cancer and analyze the gene and protein markers expressed 
specifically by tumor cell in order to be able to effectively treat the disease before tumor 
metastasis. 
1.8 Thesis Outline 
The rest of this thesis is outlined as follows. Chapter 2 will present a general 
understanding of different areas including physical, rheological properties of blood, breast 
cancer cell properties, antibody-antigen binding theory, surface modification of PMMA, 
Fluorescence analysis and blood fluid dynamics.  In Chapter 3, the surface contact area 
between the single cancer cell and the micro-channel wall will be evaluated, and three 
EpCAM/Anti-EpCAM binding models will be discussed in detail to determine an optimal 
velocity, and critical binding force. Also, fluid mechanic parameters present in the blood 
casson equation and the simulation of the 3-D velocity profile of blood flow in micro-
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channel are shown in the rest part of this chapter. Chapter 4 will describe the steps taken to 
trap and detect the cancer cells, which involve antibody immobilization on the PMMA 
micro-channel, breast cancer cell line culture, cells fluorescence staining protocols, flow 
control experiment in micro-channels and detection of cancer cell under fluorescence 
microscopy. The following chapters will discuss micro-channel geometry effects and cell 
concentration effects on the cell trap performance. Lastly, Chapter 6 will present the 





Chapter 2      Background 
Chapter 2 presents a general understanding of different areas including physical, 
rheological properties of blood, breast cancer cell properties, antibody-antigen binding 
theory, surface chemical modification of PMMA, fluorescence analysis and blood fluid 
dynamics. 
2.1 Physical, Rheological and Flow Properties of Blood 
After blood is drawn from the patients, it will flow through the functionalized micro-
channel to sieve out the breast cancer cells. Therefore, a thorough knowledge of the physical 
and fluid properties of blood is essential for understanding and modeling blood flow in the 
micro-device.  
Human blood is a suspension of cells in an aqueous solution of electrolytes and 
nonelectrolytes (Fung, 1993). Whole blood can be divided into about 55 volume % plasma, 
and about 45 volume % cells, or “formed elements” (Cooney, 1976). The hematocrit, a 
quantity of significant physiological importance, is defined as the volume percentage of 
cells, and is easily measured by centrifugation of a small blood sample (Cooney, 1976). The 
plasma is about 90% water by weight, 7% plasma protein, 1% inorganic substances, and 1% 
other organic substances (Fung, 1993).  
2.1.1 Cells Count and Morphology 
The cells consist of about 95% (by number) red blood cells (RBCs), or erythrocytes, , 
while the white cells of various categories and platelets make up less than 1/600 and 1/800 
of the cellular volume, respectively (Cooney, 1976; Fung, 1993). In human blood, the ratio 
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of the number of leukocytes to that of erythrocytes is 1 to 1000. Women have RBC densities 
of 4.8×106/µl, and men have densities of 5.4×106/µl. White cells account for 0.13% of the 
total cell count and the number of white cells ranges from 4500 to 11000/µl. The remainder, 
about 4.9%, consists of platelets. The normal range of platelet density is from 150000/µl to 
400000/µl (Cooney, 1976; Reid, 1998). 
 Human red cells, with a typical diameter of 6-8 µm and thickness of around 2.8 µm 
have the shape of biconcave disks, which can deform into a bullet-shaped entity during 
passage through small capillaries. Platelets are much smaller, having a diameter of 1-4 µm 
(Platt, 1999). The white blood cells are more rounded and include different cell types, 
including lymphocytes, monocytes, neutrophils, eosinophils, basophils. Eosinophils and 
band neutrophils are usually 9 to 15 µm in diameter, basophils average 10 to 15 µm in 
diameter, lymphocytes range in size from 6 to 10 µm, and monocytes range in size from 10 
to 30 µm in diameter (Platt, 1998). 
Red blood cells are very deformable, and they can take different odd shapes in the 
flowing blood in response to hydrodynamics stress acting on them. When flow stops, the red 
cells become biconcave. The red blood cell membrane is peculiar in that it can sustain a 
large shear deformation (the cell membrane ruptures if the area is changed by more than a 
few percent). Unlike leukocytes and cancer cells, erythrocytes are non-nucleated.  
White blood cells are the minority of cell population, and hence have little influence 
on blood viscosity. In microcirculation, however, white blood cells may adhere to the blood 
vessel wall and obstruct the flow due to the small size of the vessel. The obstruction is 








Figure 2-1  Cell Morphology and Count 
 
Breast cancer cells, with a diameter of 15~30µm, are two or three times bigger 
than red blood cells, and spherical. At the early stages of cancer, it has very low 
abundance in the blood (1~10 tumor cell in 1 ml). As adherent cells, breast cancer cells 
have a tendency to form cell aggregates. 
Figure 2-1 shows the morphology and frequency of three types of cells, erythrocytes, 
leukocytes and breast cancer cells.  
2.1.2 Blood Viscosity and Flow Curve 
Viscosity is defined as the ratio of shear stress (N/m2) to shear rate (or velocity 
gradient, 1/s) for a fluid. Figure 2-2 displays four different types of models for fluids, 
Newtonian, Power law, Bingham plastic, and Casson. If the viscosity of the fluid is the slope 
of the flow curve, the constant-slope lines corresponds to Newtonian behavior, which 
demonstrates that fluid viscosity, is independent of shear rate. Blood falls into the category 
of “Casson” curve, which is characterized by a viscosity that depends on the shear rate, and 
RBC 
Breast Cancer Cell 
WBC 
 19
also means that blood will not flow at all until a shear yield stress τy, or greater has been 
imposed on it.  
2.1.3 Effect of Shear Rate on Viscosity 
Under conditions of low shear, red blood cells have the tendency to gather, and 
"rouleaux”, which leads to a rise in viscosity (Cooney, 1976). From Figure 2-3, the apparent 
absolute viscosity of blood decreases with an increase in the shear rate. The aggregated 
RBCs break down at higher shear rates. When the shear rate exceeds 50 sec-1, no rouleaux 
exist, and the value of blood viscosity is asymptotic with respect to shear rate.  
From Figure 2-3, it is noted that nearly constant viscosity values are reached at shear 
rates above approximately 30-50 sec-1 (Whitmore, 1968).  
                               
Figure 2-2  Fluidic models (Whitmore, 1968) 
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Figure 2-3 Variation of apparent viscosity of human blood with the rate of shear 
(Whitmore, 1968) 
2.1.4 Cell-Free Marginal Layer 
It was observed by Thoma that in a tube flow, red cells tend to move toward the axis 
of the tube, leaving a marginal zone of plasma near the wall (Fung, 1993). In channels at 
least 15% wider than the cells there is a migration of the cells to the central axis of a 
capillary leaving a cell-free layer of plasma adjacent to the channel wall that can be as thick 
as 4 µm (Fung, 1993). The existence of the cell-free layer has been recorded by high-speed 
photography of the flow in vessels and glass tubes. 
2.1.5 Tube Diameter Effect 
In vivo, experimental data have shown that the apparent viscosity is a function of tube 
diameter as well as the shear rate. The dependence of apparent viscosity on tube diameter is 
known as the Fahraeus-Lindqvist effect. This interesting effect is related to the cell-free 
marginal layer, or plasma layer, adjacent to the tube wall. Since cells tend to migrate to the 
center of the tube to form an “axial accumulation”, while no cells are present near the tube 
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wall. Therefore, the hemotocrit of fluid near the wall will be reduced while that of the core 
fluid in the center of the tube will be increased (Cooney, 1976). Since the shear rate near the 
wall is much greater than that at the core, the decreased viscosity near the wall due to cell-
free marginal layer outweighs the increased viscosity at the core due to the axial 
accumulation. Taking into account these two influential factors, the increased viscosity in 
the center and simultaneously reduced viscosity at the wall, the effective apparent viscosity 
is smaller than if no cell-free marginal layer occured. It is worth mentioning that the 
reduction of the viscosity is much more pronounced for small tubes because the cell-free 
layer is a large fraction of the whole tube volume.  
Pries proposed the human blood apparent viscosities in both vivo and vitra flows. In 












































































Relative apparent viscosity, ηr, relative to the plasma viscosity, which ranges from 1.3 
to 1.7 cp. HD is the hematocrit in the vessel and d is the vessel diameter (µm). C is a curve-
fitting constant of the correlation. 
For vitro measurements, the apparent blood viscosity is a function of tube diameter 

















































The hydraulic resistance of a vessel, Re is computed with the value of the apparent 
viscosity correlation, 
 
2.2 Breast Cancer Cell Properties 
2.2.1 Comparison Between Tumor Cells and Normal Cells   
All cells have many receptors on their membrane surface, which gave communication 
between cells and their environment. Tumor cells of ectoderm origin differ from normal 
blood cells, which are mesoderm origin, in their gene expression, and each of these two cell 
populations has different tissue-specific molecules on its surface (Racila, 1998). Normal 
breast cells do not have receptors for epithelial adhesion factors, but breast cancer cells do. 
This means that breast cancers are likely to have arisen from a defect in this epithelial 
adhesion gene, which causes the receptors to be replicated numerous times on the cell 
surface.  
2.2.2 EpCAM Overexpression on Breast Cancer Cells 
Tumor cells will express specific patterns of potential target antigens. Epithelial Cell 
Adhesion Molecule (EpCAM) is widely expressed on tumor cells of various origins, 








antigen; there are on the order of 280,000 EpCAM molecules per cell. A prostate cancer cell 
line expresss lower levels of EpCAM, about 25,000 EpCAM molecules per cell. (Chianese, 
2002). The EpCAM expression of breast cancer cells makes these cells suitable targets of 
the Anti-EpCAM antibody. 
2.2.3 Epithelial Cell Adhesion Molecule (EpCAM) 
EpCAM is identified as a ~ 40-kilodalton (kd) protein in Western blotting (Yemul, 
1993). It is also known as epithelial glycoprotein 40 (EGP40), epithelial surface antigen 
(ESA), GA733-2, KSA, and the 17-1A antigen. Encoded by the GA-733-2 gene, EpCAM is 
expressed on the baso-lateral cell surface in most simple human epithelial cells. Normal 
epithelial cells, which mayexpress EpCAM are present in the lower respiratory tract, the 
lower gastrointestinal tract, the tubules in the kidney, the surface epithelium of the ovary, the 
exocrine and endocrine pancreas, secondary germ cells of telogenic hair follicles, and 
secretory tubules of sweat glands in the skin. In addition, all epithelial cells in the thyroid 
grand and the thymus express EpCAM. The outer cortex and Hassall’s corpuscles have low 
expression. In the liver, only the bile ducts appear to be positive with anti-EpCAM 
antibodies (De, 1994). Tumors arising from non-epithelial cells, such as lymphoma, 
mesothelioma, neuroblastoma, and melanoma do not express EpCAM (De, 1994). EpCAM 
has attracted attention as a tumor marker due to its expression in the vast majority of 
carcinomas (Litvinov, 1994). 
2.2.4 Tumor Cells in Peripheral Whole Blood 
At the early stage of tumorigenesis, tumor cells are shed into circulating blood, which 
makes it possible to detect cancer cells in the blood stream before the primary tumor is large 
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enough to be detected by standard screening examinations (Racila, 1998; Gross, 1995). 
Individual cancer cells can detach from a tumor, invade the blood vessels, and flow 
throughout the bloodstream until they find a suitable location, then invade new tissue and 
form a new tumor. In human blood, the only epithelial cells in the circulatory system are 
tumor cells, so EpCAM antigen over-expressed by breast cancer cells at the low frequency 
among whole normal blood cells, will be a precise precursor to detect breast cancer at the 
early stages of tumor growth and metastasis. Also, the expression of EpCAM by 
micrometastatic breast cancer cells defines these cells as suitable targets of the Anti-EpCAM 
antibody. 
The challenge of early detection of tumor cells is the extremely low frequency of 
occurrence in blood, which is 1 tumor cell in 106 normal blood cells (5~10 cancer cells per 
micro liter of whole blood). The tumor cell frequency is many orders of magnitude lower 
than the red blood cell count, however, the great differences in gene and protein expression 
between tumor cells and normal blood cells, tissue-specific molecules on the cell surface can 
be used to identify and specifically collect tumor cells of low abundance. It is vital to 
establish a sensitive and reliable method for detecting tumor cells in peripheral whole blood. 
2.3 Antibody-Antigen Interaction 
2.3.1 Antibody Structure and Function  
Antibodies are immune system-related proteins called immunoglobulins. Each 
antibody is made up of two 15000-MW polypeptide chains, designated as heavy (H) chains, 
and two 25000-MW chains, designated as light (L) chains (Kuby, 1997). Those four chains 




Figure 2-4  Antibody Structure (Kuby, 1997) 
 
The variable region, the tips of the “Y”, consists of 110-130 amino acids, and includes 
the end of both the light and heavy chains. The amino acid sequence in this variable region 
varies so greatly among different antibodies that each antibody hasa specific identity for its 
binding antigen. Treating the antibody with a protease can cleave the variable region, 
producing Fab (Fragment Antigen Binding), which retains the “antigen-binding” activity, 
and an Fc fragment, which is found to crystallize during cold storage. 
The constant region determines the mechanism used to destroy an antigen. There are 
five basic amino acid sequence patterns (µ, δ, γ, ε, and α) for the heavy-chain constant-
region sequences (Kuby, 1997). Each of the sequences is called an isotype. The heavy-chain 
constant-region structure and immune function determine the class of the antibody: lgM, 
lgG, lgA, lgD, or lgE. 
The variable region can be further subdivided into hypervariable (HV) and framework 
(FR) regions. Hypervariable (HV) regions have a relatively higher ratio of different amino 
acids than those in the framework (FR) region. HV regions are also referred to as 
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complementarity-determining regions (CDRs) because this region is directly complementary 
to the antigen. The FR regions form a beta-sheet structure to serve as a scaffold, holding the 
HV regions in position to react with antigen.    
2.3.2 Ligand-Receptor Kinetic Binding Theory 
Receptor-mediated cell adhesion plays a crucial role in physiological and 
biotechnology-related processes. The specific binding of ligands to receptors is widely used 
in molecular recognition. In the immune system, ligand-receptor binding plays an important 
role in defending the living mechanism against malignant cells and pathogenic organisms.  
The binding of receptor to a ligand is a reversible process, involving non-covalent 
bonds. Receptors bind ligands with a high-affinity lock-and–key mechanism, and the bonds 
are weaker than covalent bonds (Chang, 1996). The assumption of receptor-ligand binding is 
that the cell is brought close enough to the ligand substrate so that receptors on the cell can 
interact with the ligands on the substrate (Chang, 1999). When they are first brought to this 
position, any particular receptor is unlikely to have a ligand sufficiently close to be able to 
form a bond. As one or both reactants diffuse in their respective membranes, opportunities 
for bond formation will occur (Bell, 1978), and an encounter complex is realized. For the 
membrane-bound reactant, in general, the reaction can be conceptually separated into two 
steps. In the first step the reactants A and B simply encounter each other and diffuse on their 
membranes until they are close enough to form the encounter complex AB. In the second 
step the binding reaction occurs. The reaction may be written as  




Table 2-1  Sample Antibody/Antigen Bindings Parameters 
 
 
Receptor-ligand binding is a very complicated phenomenon, and it remains far from 
being clearly understood. Clearly the bond strength, rate of formation and dissociation of the 
ligand-receptor bindings, and diffusivity on the membrane are key determinants of the 
adhesion process, and they are the focus of many cell adhesion studies. 
 Table 2-1 shows sample receptor/ligand binding parameters (Lauffenburger, 1993), 
including kf and kr are the forward and reverse reaction rates respectively, and KD is the 
binding affinity. 
Here, TNF means tumor necrosis factor; and EGF means epidermal growth factor. 
2.3.3 Antibody Affinity  
The strength of the interactions between a single antigen-binding site on an antibody 
and an epitope is known as the affinity of the antibody for that epitope (Kuby, 1997). High-
affinity antibodies bind antigens tightly and remain bound for extended times. The 
interaction between low-affinity antibodies and antigens is weak and the bonds tend to 
Receptor Ligand RT (#/cell) kf (M-1min-1) kr (min-1) KD (M) 
Fcγ 2.4G2Fab 7.1×105 3×106 0.0023 7.7×10-10 
Chemotactic Peptide FNLLP 5×104 2×107 0.4 2×10-8    
TNF TNF 6.6×103 9.6×108 0.14 1.5×10-10 
Insulin Insulin 1×105   9.6×106 0.2 2.1×10-8 
EGF EGF 2.5×104 1.8×108        0.12 6.7×10-10     
Fibronectin  Fibronectin 5×105 7×105 0.6 8.6×10-7 
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Where k1 is the forward, or association rate constant, expressed as liters/mole/second 
(L/mol/s), and k-1 is the reverse, or dissociation rate constant, expressed as 1/second. The 
equilibrium constant K, or affinity is the ratio of the association rate to the dissociation rate. 






kK   
2.3.4 Strength of the Bond Related with Affinity 
It was presumed previously that the mechanical strength of adhesion between 
antibody-antigen complexes is related to the bond affinity. Dembo (Dembo, 1988) made the 
prediction from a theoretical model that adhesion strength is a function of the logarithm of 
the binding affinity. Experiments by Kuo (Kuo, 1993) were consistent with the prediction by 
Dembo.  
2.4 Fluorescence Technique 
Fluorescence techniques are used frequently for cell and identification. It is fast and 
precise. Since the fluorescence emission signal is shifted in wavelength away from the 
excitation signal, the detection of very low sample concentrations is possible. This aids in 
early detection and treatment. 
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2.4.1 Fluorescence Process 
In the fluorescence process, fluorochromes are excited by absorption of radiation, such 
as ultraviolet light, and then emit radiation, generally at a frequency lower than the exciting 
frequency. In Figure 2-5, fluorescence is shown as a three-stage energy transmission 
process. 
In stage 1, either the radiation source supplies the energy, hνEX, of a single photon. 
The frequency of the radiation source is νEX. Once the fluorophore molecule is hit by the 
photon, it absorbs the photon energy, and creates an excited state (S1’). This stage is defined 
as the excitation stage. 
During the second stage, the fluorophore undergoes conformational change, also 
referred to as internal conversion or vibration relaxation. The energy of S1’ is partially 
dissipated, yielding a relaxed, excited state S1. Fluorescence quantum yield is a measure of 
the quantum efficiency of different fluorophores. 
 
Figure 2-5  Jablonski Diagram 
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Fluorescence Quantum Yield = 
1 stageat  absorbed photos ofnumber 
 3 stageat  emitted photons ofnumber  
This value ranges from zero for inefficient fluorophores to one for ideal fluorophore. 
Stage three is defined as the Fluorescence Emission. A photon of energy hνEm is 
emitted and the fluorophore returns to its ground state, S0. Fluorescence is a cyclic and 
repeatable process.  
Due to the energy dissipation in stage two, the energy of the photon is lower in stage 
three. The energy difference represented by h ⋅(νEx −νEm) is called the Stokes shift. 
Fluorochromes that can be excited with the same wavelength can have different emission 
wavelengths. In multicolor fluorescence applications, different stokes shifts are required for 
the same light emission source to eliminate the overlapping bandwidth and cross talk, unless 
optics are used to filter one fluorescence or the other.   
2.4.2 Immunofluorescent Staining  
Antibodies can be visualized by tagging the antibody molecules with a fluorescent 
dye, or fluorochrome. Dye can be conjugated to the Fc fragment of an antibody molecule 
without affecting the specificity of the antibody. Absorbing light at one wavelength, the 
fluorescein dye emits light at a longer wavelength (Kuby, 1997). The emitted light is viewed 
with a fluorescence microscope, generally equipped with either mercury or xenon arc lamps, 
which produce high-intensity illumination powerful enough to image faintly visible 
fluorescence specimens, and excitation-emission filter cubes. 
There are two basic fluorescence antibody staining methods, direct and indirect 
staining. For direct staining, the specific antibody, which is also called primary antibody is 
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directly labeled with fluorescein. For indirect staining, the primary antibody is unlabeled and 
is detected with an additional fluoreochrome-labeled reagent. The most common reagent 
used is a fluorechrome-labeled anti-isotype antibody. Indirect immunofluorescence staining 
increases the sensitivity of staining because multiple fluorochrome reagents will bind to 
each primary antibody molecule (Kuby, 1997).  
2.4.3 Photobleaching 
The irreversible destruction of an excited fluorophore is photobleaching. Different 
methods are used to reduce the problem. For example, reducing excitation intensity, 
scanning for shorter times, using anti-fade reagent.  
2.5 Blood Flow Modeling 
2.5.1 Blood Flow in Large Vessels  
The behavior of blood flow in large vessels, with the diameters ranging from 0.2 cm 
~2.5 cm, is Newtonian. Utilizing the Navier-Stokes equations to describe pulsatile blood 
flow in large vessels is a correct mathematical model. 
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Figure 2-6 Poiseuille Blood Flow in Large Vessels 
 
In Figure 2-6, y is measured in the vertical direction from the bottom to the top. The 
flow conditions are well-defined as to be fully developed flow, that is, the flow field is 
independent of x; also, it is independent of time. Based on these assumptions, the governing 
equations are simplified to Poiseuille flow, which describes the steady laminar viscous flow 















Applying the lower and upper boundary conditions, 
 u=0 at y=0,  
and u=0 at y=h,  





















The volume flow rate is expressed as 












where w is the width of the channel. 

















2.5.2 Blood Flow in Small Vessels 
For pulsatile flow in small vessels, there is no single "best" model available. More 
sophisticated and more accurate measurements were needed to carry out in the future to 
identify the "correct" form of the stress-strain relations. Among all of the possible models, 
the Casson equation was a popular one because of its assumption of a yield stress - that is, 









Chapter 3     Biosystem Modeling  
To catch cancer cells on a micro-channel wall, the most important issue is to control 
the velocity of the blood sample in the micro-channel. Too large a velocity will decrease the 
time for collisions between the antibody and antigen. Too slow a flow rate will decrease the 
encounter rate. Therefore, there must be an optimal velocity to guarantee highest binding 
frequency between an antibody and antigen. In the proposed biosystem, breast cancer cells 
flow through the functionalized micro-channel and are captured by the anti-EpCAM 
immobilized on the wall.  
Hammer’s theory was adapted for this biosystem to evaluate the optimal velocity that 
would guarantee the maximum binding rate between cancer cells and antibodies found on 
the wall. Another key parameter is the critical binding force, which describes how well the 
cancer cell/PMMA surface association holds up under fluid shear. Both Bell’s kinetic model 
and Dembo’s affinity model were adapted to estimate the dissociation force. Large flow 
velocities will lead to a large shear force on the cells bound to the wall of the micro-channel. 
Comparing the critical binding force on the contact surface area of the fixed cells with the 
shear force, the critical velocity for breaking down the existed binds can be evaluated.  
In the EpCAM-mediated cell adhesion to the anti-EpCAM coated surface under the 
shear flow field, many chemical and physical factors may play a role. The key chemical 
parameters, including the EpCAM receptor density on the cell surface, the forward and 
reverse reaction rate in the EpCAM binding system, and the receptor diffusivity on the cell 
membrane were the main determinants of the number of receptor/ligand bonds formed 
during a collision and the binding force in the contact zone. The fluid force and shear stress 
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exerted on an adherent cell exposed to a shear flow will affect the receptor-ligand binding, 
and this force will counterbalance with the antibody/antigen binding force. There are also 
non-specific forces resulting from the colloidal interaction, including van der Waals forces, 
electrostatic repulsion, steric stabilization were also considered to determine if these non-
specific forces significant factors affecting the motion of the cell near the surface. 
3.1 Simulation of Anti-EpCAM and EpCAM Antigen Binding Under the Flow in 
Micro-Channel 
 
Chang Hammer’s model (Chang, 1999) was adapted to illustrate and discuss the 
relationship between the effective forward reaction rate of anti-EpCAM/EpCAM binding 
and the relative flow velocity of the antibody and antigen. This was used to model the 
effective rate of binding as a function of the fluid velocity and to determine the optimal flow 
velocity, for high capture efficiency in the micro-channel. Figure 3-1 shows a schematic of 
the MCF-7 cell captured by the anti-EpCAM/EpCAM binding with the relative velocity due 
to flow through the micro-channel.  
 
Figure 3-1  Scheme of the MCF-7 Cell Binding in Flow 
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Table 3-1  The Estimates for Parameters of the Model 1 
Parameter Definition Value 
Rp Receptor radius (Chang, 1999) 5 nm 
D Diffusion constant 10-10 cm2/sec 
Kin Intrinsic Anti-EpCAM/EpCAM reaction 
rate constant (Willuda, 1999) 
0.99 ×105/sec 
Delta Rp2Kin/D 250 
 
Table 3-1 lists estimates for parameters of the model.  
3.1.1 Flow Velocity Effects on the Binding 
In this model, the Peclet number, Pe expressed as 
 D
VR p ×  
Rp is radius of the receptor, V is the relative velocity, and D is lateral diffusivity. The 
Peclet number, Pe is a function of flow velocity and is a measure of the importance of the 
relative velocity, compared to the lateral diffusivity.  
Chang and Hammer assumed that the 2-D convection-diffusion equation. 
0)()(2 =∇⋅−∇ rCVrCD                                                (1) 
with the boundary conditions 
C (r)=C∝          at r=∝                                                   (2) 
C (r)=0         at r= Rp                                                    (3) 
The flux J through the reactive circle of radius, a (radius of the receptor), is related to 
the forward rate constant for encounter, k0, as 
∝= CkJ 0                                                              (4) 
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here k0 is given by  
DNuk π=0                                                            (5) 
The Nusselt number can be expressed as a function of the Peclet number (Equation 6) 

























n                                    (6) 


























nπ                                  (7) 
Since every encounter does not lead to a binding, the probability, P, that a colliding 
antibody-antigen pair will ultimately react needs to be determined (Moore, 1981). In Bell’s 
model, it was proposed, that for the membrane-bound receptor/ligand binding, the reaction 
was conceptually separated into two steps.  
CABBA ⇔⇔+                                                  (8) 
In the first step the reactants A and B simply encounter each other and diffuse on their 
membranes until they are close enough to form the encounter complex, AB. After that, the 
second step reaction would take place forming the bond. The theory was developed for a 
static solution, while this application required a dynamic model, in which the EpCAM 
mediated MCF-7 cell flowed on a surface with Anti-EpCAM immobilized. In the first 
reaction step, the two reactants combine ABBA ⇔+ ; with increased flow velocity, more 
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anti-EpCAM and EpCAM encounter complexes are formed. However, in the second 
reaction step, the formation of the bond through reaction, CAB ⇔ , only takes place when 
there is sufficient encounter duration time. Too large a flow velocity will take the cells away 
from the surface before the second receptor/ligand binding reaction occurs.  
Defining P as the probability that a binding event occurs before the antigen has left the 
reactive circle, yields Equation 9. 
P=kon/(kon+1/τ)                                                           (9) 
where τ is the averaged duration of an encounter and kon is the forward reaction rate of the 
antibody-antigen pair binding. When τ, the duration of the encounter increases, the 
probability of binding increases.  
Introducing a dimensionless duration time, Λ, defined as:  
Λ=τ/(a2/D)                                                                (10) 
 
   (11)  
 
By defining a dimensionless number, δ, relating the probability of reaction to 
diffusitivity:  
δ=a2kon/D                                                                 (12) 
The probability of binding, P, changes to the form in Equation 13. 








































Combining the forward rate constant, k0, and probability, P, yields the effective 
reaction rate (Equation 10), 
 )1 /(0 δ δ π π Λ + Λ = = = DNu DNuP Pk k f                                  (14) 
For each type of receptor/ligand binding, the dimensioness number, δ, is determined 
by intrinsic reaction rate. All of the key values are a function of the Peclet number, or flow 
velocity.  
3.1.2 Determination of the Optimal Flow Velocity for Binding 
From the equation, k0 = DNuπ , the forward rate constant, k0, is proportional to the 
Nusselt Number, Nu . Equation 7 expresses the calculated Nusselt number as a function of 
the Peclet number and is plotted in Figure 3-2. The relationship is nearly linear and 
mathematically increasing.  
The dimensionless duration time, Λ, is also a function of the relative velocity through 
the Peclet number, Pe. The duration time Λ decreases rapidly with increasing Pe. Plotting 
non-dimensional effective reaction rate constant (Equation 11) for different values of δ yiel 
Figure 3-4.  
For anti-EpCAM and EpCAM binding,δ, (a2kin/D) is a function of the  
antibody/antigen binding affinity and equal to 250. From Figure 3-4, the curve with δ equal 
ti 250, the dimensionless forward effective reaction rate constant kf / D initially increases 
with Pe (relative velocity) and until it reaches a plateau when Pe is ~1000. When Pe (RpV/D) 
reaches 1000, the effective reaction rate reaches a maximum. The optimal flow velocity is 
 V=Pe×D/Rp=2 mm/s 
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Figure 3-4  The Dimensionless Effective forward reaction rate constant kf / D as a function 
of Pe 
 
From Figure 3-2, increased Peclet number, which represents the relative motion 
between antibody and antigen, leads to a higher forward encounter rate of binding. As the 
convection velocity increases the encounter rate, the reaction rate of antibody-antigen 
binding is enhanced. 
However, from Figure 3-3, the duration of each encounter between an antibody and 
antigen pair decreases with the increase of the Peclet number. While increasing the relative 
velocity increases the encounter rate between antibody and antigen, the duration time for 
molecules to react with each other decreases.  
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Equation (10) combines the two factors influencing the effective reaction rate, 
encounter rate and duration time, and yielding the relationship between the effective reaction 
rate and the Peclet number. From Figure 3-4, the reaction rate increases with Pe (relative 
velocity) and then reaches a plateau. This indicates that convection enhances the rate of 
collision and the antibody-antigen reaction rate (Chang, 1999). As the fluid flow rate 
increases, the rate of encounter between antibody and antigen rises monotonically, but 
decreases the collision duration (Chang, 1999). The net effect is that the forward rate 
constant will rise up to a plateau as these two effects counterbalance each other. 
3.2 Micro-Channel Diameter Effect on Viscosity Determination 
 
In low Renold number flow, the shear rate can be simply calculated as the ratio of the 
flow rate to half of the width of the tube. In the micro-channel of 20 µm width at a flow rate 
of 2mm/sec, the shear rate is approximately 200 sec-1, greatly above the required shear rate 
(30-50 sec-1) for constant blood viscosity. For our design, we can safely assume the constant 
viscosity. However, we still need to consider the Micro-channels geometries effect on blood 
viscosity. 
In vitra measurement, the apparent blood viscosity as a function of tube diameter and 


















































Figure 3-5  Micro-Channel Geometry Effect on Blood Viscosity 
The equation for the hydraulic diameter is, 
P
Ad 4= , where A is the cross sectional 
area and P is the perimeter.Here, d and Hemocrit, HD, are defined as 27 µm and 0.4, so the 
apparent blood viscosity in the micro-channel (15µm × 150µm × 4mm) is calculated as 2 cP. 
From Figure 3-5, blood viscosity increases with the increasing hydraulic diameter. 
3.3 Comparison of Forces 
Chang and Hammer (1996) compared the different forces applied to the cell/surface 
attachment.  Figure 3-6 defines the geometry used in this model, with a, the radius of the 
cancer cell; h, the closet separation distance between the cell and the substrate; L, the bond 





Figure 3-6 Comparison of Applied Forces on a Single Cell/Surface Attachment 
At equilibrium the balance of forces in the x-direction gives: 
φcosTF =                                                            (16)        
The torque balance gives, 
)cos( φθτ +−= Ta                                                     (17) 
The bond length, L, ranging from 20 nm to 40 nm, is much smaller than the radius of 
the cancer cell, a, at the average level of 12 µm. Based on this geometry, with a>>L, the 
assumption was made that θ is small, and φ is near to 90°. The detailed calculation of forces 
comparison is shown in Appendix 2. The relationship between the shear force, F, and the 






                                                    (18) 
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For a typical value of bond length in average, L is 25 nm, the characteristic separation 
distance, h, is approximately 20 nm (Chang, 1996). Since the mean cancer cell radius is 12 
µm, the ratio between the shear force and the normal force was approximately 0.03. The 
required normal force to break a single bond is approximately 33-times greater than the 
shear force. The shear force is much more disruptive of the bond than the normal force. 
Therefore, among all of the forces applied to detach an MCF-7 cell from the surface, the 
shear force is the most likely to rupture the antibody-antigen bond and the other forces are 
so insignificant that that they can be ignored in the model. 
3.4 Estimation of the Critical Binding Force and the Dissociation Velocity for 
Breaking the Bonds 
 
Cancer cells captured by the anti-EpCAM/EpCAM binding force on the functionalized 
PMMA surface are exposed to a flow field relative to the PMMA. This is similar to the 
situation in which a balloon tied to a string under a strong wind. In the fluid flow field, a 
larger flow velocity will produce higher shear forces on the captured cells. Fluid flowing 
through the channels exerts forces on the cells already captured on the micro-channel wall. 
If the flow rate is too high, the flow disruption will be significant enough to uproot the cell 
from the wall. 
To avoid the cells already caught on the wall from being dislodged by the large shear 
force, both the Bell kinetic model and Dembo affinity model were adapted to estimate the 
shear force required for dissociation as well as the critical flow velocity at the forces needed 
to break the bonds. The objective was to find the critical binding force, shear velocity, and 
shear modulus.  
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3.4.1 Contact Area Evaluation 
Knowing the number of bonds per unit area and the contact area, the net binding force 
in a contact area can be evaluated. The area of the contact zone for a smooth, relatively non-
deformable particle can be estimated using the geometry of the Cozens-Roberts model 
(Cozen-Robert, 1990). Applying this model the values for the contact region radius for 
assumed rigid cell were estimated. 
The parameters in the schematic (Figure 3-27) diagram are: a, the radius of cancer 
cell; h, the separation distance between the cell and PMMA substrate coated with anti-
EpCAM, and H, the maximum separation distance for the antibody-antigen binding; and r, 
the radius of the contact area. From this geometry, the relationship between h, H, and r was 
derived. Define h* and a* as shown in Figure 3-7: 
hHh −=*                                                           (19) 
and                                                            


















From the  Figure, θ and r are given by: 
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                                  (22) 
According to the dimensions of IgG, ∼19×57×240
o
A  (Clausen, 1981), the 
characteristic separation distance, h and H are estimated to be ∼100 
o
A  and 400
o
A . The 
representative radius of the MCF-7 cancer cells, a, was taken to be 12 µm. The radius of the 
contact area was calculated with this model as 0.85 µm (H=0.04 µm and h=0.01µm) based 
on the above equation. The contact area, A, has a value between πa2 and 2πa2, depending on 
the curvature. Here, the factor of 2 is considered within level of uncertainty.  In this model, 
A was calculated to range from 2.27 to 4.54 µm2 and a mid-range value of 3.5 µm2 was 
chosen. 
3.4.2 Model I: Binding Force Determination Developed from Dembo Binding   
Affinity Model 
 
Receptor-mediated cell adhesion is a central phenomenon in many physiological and 
biotechnological processes. The mechanical strength of the adhesion is generally presumed 
to be related to the chemical affinity of the receptor/ligand bonds. Antibodies with low 
affinity bind antigens weakly and tend to disassociate easily, whereas antibodies with high 
affinity bind antigens more tightly and longer. 
In Kuo’s model (Kuo, 1993), it was demonstrated that the adhesion strength varies 
with the logarithm of the binding affinity, consistent with a prediction from the theoretical 
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model by Dembo et al (Dembo, 1988). In Dembo’s model, the critical tension, Tcrit, was 














                                                  (23) 
The variables were kB, Bolzmann’s constant; θ, the absolute temperature; NL, the 
substratum ligand density; α, the front angle between the membrane and the surface; NR, the 
cell receptor density, and KD, the dissociation constant. 
The surface energy for binding between the cell membrane and surface was defined as 






                                                    (24) 
 Evans [11] showed that an alternative expression of surface energy in terms of the 
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where lb is the extent of stretch to reach the critical force to break down the single bond. The 












+=                                               (26) 
Here, KB=1.38×10-23 J/K, θ=298K. 
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Table 3-2  The Parameters Used in Dembo Affinity Model Applied to anti-EpCAM/EpCAM 
Binding 
 
Parameter Definition Value 
A Radius of cancer cell 12 µm 
N EpCAM molecules number on single 
breast cancer cell 
280,000 
NR Cell EpCAM receptor density 1.6×1010#/cm2 
kon EpCAM/Anti-EpCAM forward rate 
constant (Willuda, 1999) 
0.99×105/mol⋅sec 
kr EpCAM/Anti-EpCAM reverse rate 
constant (Willuda, 1999) 
0.3×10-3/sec 
KD EpCAM/Anti-EpCAM binding affinity 3×10-9M 
NL Substratum ligand density 3.5×1012/cm2 
lb Extent of stretch to reach critical force 8.8A 
η Fitting specificity (Kuo, 1993) 1.3×1018#-liter/cm2-mol 
Ac Contact area 3.5 µm2 
 
Using the parameters in Table 3-2, the critical force to break one EpCAM-antiEpCAM 
bond, fc, was 6.7×10-6 dyne. If the assumption that cells are relatively non-deformable was 
made, the critical force, the sum of that all of bonds in the contact zone (3.5 µm2) was 
calculated as 3.6×10-3 dyne.  
3.4.3 Model II: Binding Force Developed from Bell Kinetic Model 
In the second model, the same as in the model I, the goal was to estimate the 
magnitude of the critical dissociation force needed to break down the attached bonds in the 
contact zone, and further estimate the critical flow velocity at which all of the adherent 
ligand-receptor bonds would rupture rapidly. 
Assume that the breast cancer cell is attached to the PMMA substrate surface by many 
bonds. To separate the cell, a force is required that will fairly rapidly rupture each bond.  If 
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E0 is the energy change in binding and r0, is the range of minimum, then the net force f0=1 .6 
×10-5 E0/r0. 
If force, F, is tending to separate the cells, and assuming that each bond is equally 
stressed, the force per bond is F/Nb and the reverse rate constant are replaced by, 
                                                           (27) 
when N2>>Nb,  
                              (28) 
A critical force, Fc, which is determined as just sufficient to detach the cell from the 
PMMA substrate. It is straightforward to show that the critical force per potential bond, fc 









                                                       (29) 
where αc is obtained from:  
Rcc KN=+ )1exp(αα                                                       (30) 
Using the parameter values in the table, the critical force to break down one EpCAM-
anti-EpCAM bond, fc, was 6.7×10-6 dyne. This value was the critical force to break a single 

















Table 3-3 The Parameters Used in Bell Kinetic Model 
 
Parameter Definition Value 
kon Forward rate constant (Willuda, 1999) 0.99×105/mol⋅sec 
kr Reverse rate constant (Willuda, 1999) 0.3×10-3/sec 
K Equilibrium constant 3.3×108M-1 
NR Receptor density 160/µm2 
r0 Separation distance between molecules at the 
minimum breaking force 
0.5 nm 
Ac Contact area 3.5 µm2 
 
Assuming that the EpCAM receptors on the cancer cell membrane are uniformly 
distributed, the number of bond pairs in the contact zone can be expressed as, Ac×NR, and 
the total force, F, to remove the cell from the contact surface is, 
 
From a lot of experiments, the result shows that about a factor of 3 smaller than the 
earlier estimate of the force f o needed to completely dissociate a bond. The critical force 
will provide a reasonable estimate of the force required to separate two cells or a cell from a 
surface. The models could also be applied to evaluate the optimal velocity and critical 
binding force in the capture of any other type of cancer cells. 
3.4.4 Increased Dissociation Force due to Cell Response to Binding 
 
 
Figure 3-8  Cell Spreading Response to Binding 
dynesNAN Af F RcRcc
36 107.3107.6 −− ×=××=××=
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Small, round cells recognize and bind to immobilized ligands, adhering to the tissue-
specific substrate. After initial contact, the small, round MCF-7 cells flatten and elongate. 
The enlarged contact area makes dissociation more difficult than predicted by the models, 
which assumed non-deformable cells. Using a soft lithography-based micro-patterning 
technique originally developed in Whitesides' laboratory at Harvard, the surface contact area 
can be measured (Singhvi, 1994). For example, the typical diameter of a hepatocyte, an 
epithelial cell of the liver, is 20 µm, whereas upon attachment and unconstrained spreading, 
the cell diameter increases to 30–40 µm. After attachment, cells were observed to elongate 
in the axial direction upon spreading (Singhvi, 1994). 
According to the theory of cell spreading response to attachment, once the cell is 
adhered to the wall, it will flatten, which results in an increase in the tightness of binding. 
The deformable MCF-7 breast cancer cell has a larger contact area than the 3.5 µm2 
predicted in the non-deformable Cozen-Robert model. The surface contact area radius was 
assumed to be around 12 µm, much larger than 0.85 µm, evaluated in the Cozen-Robert 
model. This yielded a contact area of 452 µm2. The critical binding force to uproot the 
whole cell from the substrate is the product of the critical force for a single bond and the 
number of bonds in the contact area. The force was also assumed to be evenly distributed 
over the bonds in the contact zone, so the critical binding force was linearly proportional to 
the number of bonds in the contact area. A more accurate estimate of the binding force 
between a breast cancer cell and the PMMA substrate is, 
dyneNANAfF RcRcc 48.0107.6
6 =××=××= −  
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The whole number of bonds in the contact area was estimated to be Rc NA × =72345. 
The spreading of the MCF-7 cells on the antibody-modified PMMA substrate resulted in an 
increase in the number of bonds and a more than100-fold increase in the adhesion strength, 
which made the detachment more difficult.  
Different cancer cell lines, express different numbers of EpCAM molecules on their 
surfaces, so the critical binding force between EpCAM and anti-Epcam varies among them. 
For a prostate cancer cell line, 25,000 EpCAM molecules are expressed on the cell surface, 
with the number of bonds generated in the contact zone is 6577' =× Rc NA . From Figure 
3-9, for the prostate cancer cell line, the net dissociation force is 0.042 dyne, more than 10-
times smaller than for the breast cancer cells which over-expressed the EpCAM. 
 
Figure 3-9 The Critical Binding Force for different types of Cancer 
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3.4.5 Dissociation Velocity  
 From Chang and Hammer’s comparison of different applied forces, it was known that 
the shear force was the most destructive. To estimate the critical flow velocity required to 
break the antibody and antigen bonds, it was assumed that when the shear force equaled the 
total binding force, the bonds would break. A relationship between the critical flow velocity, 
v, and shear force was determined. When a stationary cell of radius, r, is exposed to a fluid 
stream of velocity, v, the force on the cell will be given by Stokes law (Bell, 1978). 
rvF πη6=                                                              (31) 
In our model, η is the blood viscosity, 2 cp, and r is breast cancer cell radius, 12 µm. 
Comparing this hydrodynamic force with the critical binding force of 0.48 dynes determined 
from Models I and II, the dissociation velocity, at which the hydrodynamic shear force will 













This means that the breast cancer cell held by 72345 bonds in the contact area can 
resist fluid velocities less than or equal to about 10.6 m/sec. The prostate cancer cell, which 
is held by 6577 bonds, can only resist a fluid velocity of ≤92 cm/s. 
3.5 Life Time to Break the Bonds 
Each bond is reversible and the lifetime of a bond, τ, is written (Evanse, 1985) 
τ=τoexp[(Eo-γf)/kT]                                                   (32) 
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In which t is the time to separate cell from surface subject to the force. E0 is the bond energy, 
f is the applied force per pond, τ0 is the reciprocal of a natural frequency of oscillation of 
atoms in solids. γ is a parameter determined to account for the structure of the solid and its 
imperfection. The lifetime is a function of f and T. If representative values for the antibody-
antigen bond are taken as shown in Table 3-4 to be τ (f =0) ≈ 0.01 second, then τ0=10-8 
second (Bell, 1978).  
Using the parameter values cited in Table 3-4, the values for the bond lifetime are 
given in Figure 3-10 (Bell, 1978).  
Table 3-4  The Parameters Used in Bond Lifetime Model 
 
Parameter Definition Value 
γ Dimension of the binding cleft 0.5nm 
E0 Bond energy 0.37ev 
T Temperature 310K 




Figure 3-10 The single bond life time at different applied forces 
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In Figure 3-10, when there was no applied force, the lifetime for a single bond was 
0.01 sec, and the bond lifetime decreased dramatically with the increase in the applied force.  
When the applied force was smaller than the integrated binding force in the contact 
area zone, the cell will remain anchored to the substrate; however, for the applied force 
larger than the binding force among all the bonds, cells will detach from the substrate 
rapidly.  For the applied forces much larger than the critical force, fc, the time, T to detach 










=                                                          (33) 
Here, KTfrY /00 =  
Figure 3-11 displayed how rapidly the cell detached the surface once the applied force 
larger than the critical binding force was applied.  
 
Figure 3-11 The cell/surface separation time at applied forces much larger than the critical 
force 
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From Bell kinetic model and Dembo binding affinity model, the same single binding 
force, 6.7×10-6 was obtained for Anti-EpCAM/EpCAM binding. It was shown in Figure 
3-11 that when this critical force was applied, the time for an MCF-7 cell to detach from the 
PMMA substrate would be on the order of 0.1 sec. When the larger forces were applied, the 
cell would be separated from the surface more rapidly and easily.  
3.6 Nonspecific Force in Antibody/Antigen Binding 
When whole cells or cell membranes are used for receptor/ligand binding, a ubiquitous 
problem is the occurrence of non-specific interactions, such as van der waals attraction 
between hydrophobic regions of interacting membranes, electrostatic repuslsion between 
charged cell surfaces, and steric stabilization (Bell, 1978). Generally, cells carry a net 
negative electrical charge and tend to repel each other because of the repulsive electrostatic 
force. In addition, the van der Waals force is attractive and has a longer range than the 
repulsive electrostatic forces. This suggests that cells will repel each other up to a certain 
distance and then be attracted to each other. In numerical calculations, this separation 
distance was estimated as around 10 nm. The corresponding non-specific forces needed to 
separate the cells were estimated to be around 10-5 dyne per square micrometer of cell area 
(Bell, 1978). Multiplying this value with the estimated contact area of 452 µm2, the resultant 
force to detach the cell from the surface turns out to be only 4.5×10-3 dyne, more than 100-
fold smaller than the specific binding force calculated as 0.48 dyne. Therefore, it is apparent 
that specific bonds can cause cells to adhere to the surface much more tightly than the 
nonspecific forces, and the nonspecific forces can be negligible with respect to the specific 
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binding force. Also, cells separated by distances of 10 nm should have opportunities for 
contact and the formation of the specific bond. 
Understanding cell adhesion completely requires more quantitative feeling for each 
basic interaction involved in receptor-ligand binding shown in Appendix 1 (Bongrand, 
1984).  
3.7 Blood Flow Modeling Using Casson Equation  
For blood pulsatile flow in small vessels, there was no single "best" model available. 
Among all of the models, the Casson equation has been popular because of the assumption 
of a yield stress - that is, the necessity of an initial state of stress in order to start the blood 
flowing. 
The stress-strain equation was expressed as, 
yv τητ += &                                                  (34) 
The yield stress τy in the above equation was related to the hematocrit of the blood, H. 
3)625.0(1.0 Hy ⋅=τ                                                 (35) 
The volume flow rate of blood was derived having the same expression as Poiseuille 









                                              (36) 
where, ε is a parameter related to the yield stress (τy), vessel diameter (D), and the pressure 
drop (
dX
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For a micro-channel with a hydraulic diameter of 27 µm, the pressure drop was 
calculated: 7585 Pa=1.1 psi. Solving these equations, the pressure drops for micro-channels 
with different diameters were calculated. 
Figure 3-12 displayed the according pressure drop in micro-channels with different 
diameters. With the increase of the diameter of the micro-channel, the pressure drop 
decreased. 
The 3-D velocity profile of the blood flow in the micro-channel was displayed in 
Appendix 3.  
Table 3-5 The Parameters Used in Blood Casson Flow 
Parameter Definition Value 
W Width of Micro-channels 15µm 
H Height of Micro-channels 150µm 
L Length of Micro-channels 40mm 
N Number of parallel channels 17 
D Hydraulic diameter 27µm 
H Hematocrit of blood 0.4 
τy Yield stress 1.56×10-3Pa 
ηplasma Plasma viscosity  0.0012Pa⋅sec 
η Blood viscosity 0.002Pa⋅sec 
V Flow velocity 2mm/s 












































Chapter 4     Experiment 
In this chapter, the experimental steps taken to trap and detect the cancer cells were 
described. It involves antibody immobilization on the PMMA micro-channel, breast cancer 
cell line culture, cells fluorescence staining protocols, flow control experiment in micro-
channels and detection of cancer cell under fluorescence microscopy. 
4.1 Immobilization of anti-EpCAM on the PMMA Micro-Channel 
4.1.1 Protocol for Surface Modification of PMMA Micro-Channel 
A functionalized PMMA micro-channel was designed to trap the rare breast cancer 
cells from peripheral blood flowing through the micro-channel. Breast cancer cells over-
express EpCAM on their surfaces, and will be caught by the strong binding affinity between 
the antibody and antigen, after anti-EpCAM antibodies are immobilized on the polymer 
micro-channel walls by the chemical surface modification of PMMA.  
Figure 4-1 shows Poly (methyl methacrylate). The transition temperature (Tg) of 
PMMA is around 105°C. There are two reasons why PMMA was used as the material for 
the micro-channel. The first, was that the functional group, methyl ester, has chemistry 
modification potential; the second, was tjat PMMA is extensively used as a resist in 
lithographic applications in MEMS, and micro-fluidic devices. 
 
Figure 4-1 Poly(methyl methacrylate) 
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The surface modification protocols composed three steps. First, UV radiation 
illuminated the PMMA surface to get carboxyl group-modified PMMA, Then 
Ethylenediamine, (H2NCH2CH2NH2) was added to yield amine-functionalized PMMA. 
Finally, the antibodies were attached, and sufficient reaction time to generate tethered 
antibodies on the PMMA micro-channel was allowed. This antibody-functionalized PMMA 
was prepared for targeting breast cancer cells. The protocol is listed schematically as 
follows, 
 
4.1.2 UV Modification of Micro-Channel 
Commercial PMMA substrates as thick as 3 mm were obtained from Atofina 
(Philadelphia, PA). 
1. Clean Channel; 
2. Expose the micro-channel to UV; 
3. Align the coversheets on the micro-channel and drilled holes on the coversheets; 
In the first step, the PMMA micro-channel was placed into the sonicator for 20 
minutes to get the particles and dust removed, and then the microchip was rinsed with IPA, 
and DI-H2O respectively. Lastly, dry blow the chip with a stream of nitrogen.   
In UV radiation step, the prepared microchip was placed on the platform of UV light 
station, with the front side of hot embossed micro-channel facing the UV light for 20 
UV 
PMMA COOH-Modified PMMA 
NH2~NH2   
NH2-Modified PMMA
Anti-EpCAM 
  Anti-EpCAM Modified PMMA 
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minutes. The distance between the UV light source and platform is 3 cm. Take the PMMA 
micro-channel away from UV light, and wash once with IPA and DI-H2O individually. 
For aligning coversheets on the micro-channel, two pieces of PMMA coversheet as 
thin as 0.5mm were prepared. On one piece of coversheet, two holes were aligned and 
drilled according to the landscape of PMMA micro-channel reservoirs. This coversheet is 
put on the front side of micro-channel, and the other coversheet is put on the backside of the 
micro-channel. Stack the micro-channel with the two PMMA coversheets together in the 
middle of two pieces of square glass, and use binder clips to clamp the glasse on four sides 
to reinforce and level. These two pieces of coversheets design has less objective distance 
(0.5 mm) to reach micro-channel than that (3mm) of the one piece coversheet design, hence 
showing is shown better image in microscopy than one piece. 
The UV exposure step was extremely sensitive. Too long an exposure time or too 
small a distance between the UV source, and the substrate would destroy the PMMA micro-
channel structure.  
X-ray Photoelectron Spectroscopy (XPS) was used to confirm that the functional 
carboxyl group (COOH) was tethered to the PMMA after UV exposure. This was performed 
by Dr. McCarley’s group at LSU Chem. Dept.  
4.1.3 Thermal Bonding 
The prepared micro-channels were heated in the thermal bonding oven displayed in 
Figure 4-2. The holding temperature was set at 105°C, the glass transition temperature for 
PMMA, and the holding time was ten minutes. The temperature drops to 50°C eventually.  
 64
 
Figure 4-2  Varian 3400 Gas Chromatograph 
 
After the micro-channel was taken out of the oven, the coversheets and the micro-
channel substrate were bonded together with the micro-channel geometry intact.  
4.1.4 Preparation of NH2-Modified PMMA Surfaces 
The reaction between COOH-modified PMMA and H2NCH2CH2NH2 is shown in         
Figure 4-3. 
 
Figure 4-3 The reaction between COOH-modified PMMA and H2NCH2CH2NH2 
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The procedure is listed as follows,  
1. Prepare amine functionalization solution; 
2. Draw solution into micro-channel by vacuum; 
3. Shake and incubate for 60 minutes; 
4. Repeat step 3, and nitrogen dry; 
After thermal bonding, the PMMA channels were enclosed by the coversheet, except 
that the two holes at the ends were open to the air for adding the chemical reagents. The 
Amine function solution was prepared by adding 0.0065 g EDC, and 10 µl Ethylenediamine 
expressed as H2NCH2CH2NH2 to 1 ml PBS (PH=7.4). Here, EDC is developed as a carboxyl 
(COOH) activating agent for amide bonding with primary amines.  
 
Figure 4-4  Experiment of Set up for Chemical Surface Modification of PMMA Micro-
Channels 
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In the second step, the solution was dropped to one end of fluid reservoir. Vacuum 
the other end of reservoir with the use of the pump to suck the amine function solution into 
the micro-channel as followed experimental demonstration in Figure 4-4.  
During incubation step, shake the microchip for a while for freshly prepared amine-
modified solution to contact the inner surfaces of the micro-channel adequately and keep the 
solution in the channels for 60 minutes. The second round solution was added and remained 
in the channels for 30 minutes. At the end, dry it under a stream of nitrogen. 
4.1.5 Preparation of anti EpCAM-Modified PMMA Surfaces 
The primary antibody, anti-EpCAM, was obtained from Oncogene (San Diego, CA). 
This monoclonal antibody recognizes and reacts with the human EpCAM antigen. The 
antibodies are formed from the clone VU-1D9 derived by immunizing mice with NCI-H69 
small cell lung carcinoma cells. The isotype is mouse IgG.  




Figure 4-5 The reaction between NH2-modified PMMA and anti-EpCAM 
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The procedure of immobilization of Anti-EpCAM was listed as follows,  
1. Prepare the primary anti-EpCAM antibody solution; 
2. Flow the antibody solution through the micro-channel; 
3. Incubate the antibodies in the channel overnight; 
4. Rinse the micro-channel with PBS, and dry it with nitrogen.  
5 µl of anti-EpCAM supplied at 1µg/µl in phosphate buffered saline (PBS), and 
0.0008g EDC, were added to100 µl PBS. The final concentration of antibody is 50µg/ml. 
The same flow system shown in Figure 4-4 was used to flow antibody through the PMMA 
micro-channels. 
Leave the antibodies in the channel overnight at 5°C, and then dry the channels 
under a stream of nitrogen. Lastly, rinse the micro-channel with phosphate buffer solution 
(PBS). The antibody-modified PMMA micro-channel is prepared. 
4.1.6 Visualization of Anti-EpCAM-Modified PMMA Micro-Channel 
To test if anti-EpCAM could be immobilized on the PMMA micro-channel using this 
surface modification protocol, an antibody labeled with fluorochrome was used. If an 
antibody functionalized micro-channel is obtained, the fluorescence along the inner channel 
wall could be demonstrated with the fluorescence microscopy. Direct and indirect bondings 
were compared to determine which method generated better antibody immobilization. 
For the indirect method, a secondary antibody, Fluorescein (FITC)-Donkey Anti-
Mouse IgG, provided by Jackson ImmunoResearch (West Grove, PA) was used to react with 
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the primary antibody. Figure 4-6 demonstrates the immobilization of anti-EpCAM by 
indirect labeling.  
This process is accomplished by adding one more step after the anti-EpCAM 
modification PMMA micro-channel. Draw 4 µl of secondary antibody, FITC-Donkey Anti-
Mouse IgG (1.4mg/ml) into 200µl PBS. The dilution ratio is 1:50. Remain this secondary 
antibody in the anti-EpCAM modified micro-channel for 2 hours at 5°C. Last, dry blow the 
channels with nitrogen and rinse it with PBS. 
In Figure 4-6 the bright green along the micro-channel, showed that the anti-EpCAM is 
immobilized on the inner channel wall. The indirect staining increased the sensitivity of the 
staining because multiple fluorochrome reagents will bind to each primary antibody 
molecule. 
 
Figure 4-6  Immobilization and Fluorescence Image of anti-EpCAM by Indirect Labeling 
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For direct labeling, anti-EpCAM labeled with FITC replaced pure Anti-EpCAM. 
Figure 4-7 shows the immobilization of anti-EpCAM-FITC by direct labeling and displays 
the fluorescence image of the anti-EpCAM immobilization using the direct method. A very 
weak green line was evident along the channel wall.  
There are two reasons why indirect labeling showed better results than direct labeling. 
For direct staining, the concentration of anti-EpCAM labeled with FITC, 12.5mg/ml, was 
too low, and in the small volume of the micro-channel, there were not enough antibodies 
immobilized. Also, FITC also interacts with the amine groups, so it inhibited the effective 
reaction between the antibodies and amine group and decreased the coverage of the antibody 
along the channel. 
 
Figure 4-7  Immobilization and Fluorescence Image of anti-EpCAM by Direct Labeling 
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4.2 Breast Cancer Cell Line MCF-7 Culture 
4.2.1 Cell Line Description 
MCF-7 from ATCC (Manassas, VA) was kindly provided from Dr. Truax from 
Veterinary School in LSU. This breast cancer cell line can be described in Table 4-1. 
Table 4-1 Breast Cancer MCF-7 Cell Line 
Organism Homo sapiens (human) 
Tissue breast; mammary gland; adenocarcinoma 
Morphology epithelial 
 
Cell lines were grown in Dulbecco’s Modified Eagle’s Medium with high glucose 
(DMEMHG) containing 1.5 g/L sodium bicarbonate (NaHCO3), 15 mM HEPES buffer, and 
10% fetal bovine serum (FBS). In cell culture medium, HEPES is an organic buffer used to 
maintain physiological pH in CO2 incubator. For the experiments, MCF-7 cells were 
suspended in the culture medium. The cell sizes ranged from 15 µm ~30 µm. Figure 4-8 
shows a single MCF-7 cell under optical microscopy. 
 
Figure 4-8 Single MCF-7 Cell under Optical Microscopy 
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4.2.2 Cell Counting Using a Hemacytometer 
A hemacytometer was used to determine the MCF-7 cell concentration. It is an etched 
glass chamber with sides that will hold a coverslip exactly 1 mm above the chamber 
floor. The process of cell counting is listed as follows: 
1. Disseminate cells very well until all the clumps are broken up; 
2. Using a sterile Eppendorf pipette, draw a 100 µl cell sample into a micro 
centrifuge tube; 
3. Put 100 µl trypan blue (0.4%) from Sigma into the tube with cells to differentiate 
the dead cells (darker blue) and healthy cells (brighter blue) shown in Figure 4-9. 
4. Mix 20~25 times with Eppendorf pipette and load onto hemacytometer.  
5. Count four corner squares on the top and bottom of the chamber. 
 
From the cell counter, there were 165 cells counted in 4 squares. 
 
Figure 4-9 Counting MCF-7 Cells with a Hemacytometer 
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Cell Concentration (Cells/ml)  
=Cell counted × depth of hemacytometer (0.1 mm depth) × dilution factor × 103 / No. 
of square counted 
=
4
10210165 3××× =8.25×105cells/ml. 
In the total 2.5 ml cell sample volume, there were 2×106cells. 
The viability was defined as the concentration of all live cells among the whole cells. 
Dead cells have protein and enzymes, so they may react with stain, or fade the dye. The 
viability in our sample cells was recorded generally as 80%, which is very good in standard.  
4.2.3 Medical Handling of the Human Cell Line and Biosafety  
Appropriate safety procedures should be used when handling all cell lines, especially 
the human cell line. Protective gloves and lab coats were always used and a full mask was 
worn when handling the cells.  
The waste was disposed of properly. The unfinished MCF-7 cell line was put into a 
big plastic ware container with heavy-duty soap, such as 7×cleaning solution from Linbro or 
Clorox detergent. They were left in the sink for more than 10 minutes until the harsh 
detergent killed the cells, and then discarded in the sink.  
Disposable plastic tubes were used and discarded in biohazard bags. These were high 
temperature sterilized at a special facility on campus. Needles or sharps materials were put 
into a puncture resistant container.  
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4.3 Detection Design by Multi-Fluorescence Technique 
To validate the capture of the rare breast cancer cells, three fluorescence markers, each 
identified by a separate color, were used to reliably identify the cancer cells. DAPI was the 
nuclei dye, which stained the nuclei of cells. White blood cells were stained with PE-CD45, 
which showed in orange under fluorescence microscopy. The cancer cells were defined by 
DAPI+ (blue), and the FITC-cell membrane linker+ (green). White blood cells, which will 
interfere in the detection of the cancer cells, were identified by DAPI+ (blue), CD45+ (red), 
and the FITC-cell membrane linker+ (green). Red blood cells do not have nucleus, so DAPI 
(blue) cannot stain them. Single color controls and unstained (autofluorescence control) cell 
samples were also run initially. In Table 4-2, cancer cell and white blood cells were 
compared with the use of three fluorochromes.  
Figure 4-10 shows the schematically how the different types of labeled cells would be 
observed under fluorescence microscopy. 
The Microphot fluorescence microscope from Nikon had an Epi-illumination mercury-
arc light source. The microscope contained a trinocular observation head that was coupled to 
a charge-coupled device (CCD). The broadband source was able to excite many different 
fluorochromes. The Mercury-arc light source was a broadband illumination source, and 
produces a blue-green light that is rich in ultraviolet and near-infrared light region. Figure 
4-11 shows the Mercury-arc lamp emission spectrum. Excitation and emission filter cubes 
for FITC and DAPI are B2 and UV-2, respectively. 
The excitation-emission wavelengths for DAPI, PE and FITC are listed in Table 4-3. 
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Table 4-2  Multi-Fluorescence Comparison between Breast Cancer Cells and White Blood 
Cells  
 
     Florescence 
Cell Type 










+ − + 
 
Blue in nuclei, and 




+ + + 
 
Orange, Blue in nuclei, 






Figure 4-10 Multi-Fluorescence Technique Used in Breast Cancer Detection in Micro-
Channel 
 
Table 4-3  Three fluorochrome Markers in the Detection Design 
 
 Excitation (nm) Emission (nm) Fluorescence color 
DAPI 350 458 Blue 
(Phycoerythrin) PE 480-565 578 Orange-red 




Figure 4-11 Mercury Arc Lamp Emission Spectrum (Olympus BioSystems, Planegg, 
Germany) 
4.3.1 DAPI Staining 
DAPI nucleic acid stain was obtained from Molecular Probes (Eugene, OR). It is a 
popular dye for use in multicolor fluorescent techniques. DAPI stains only the nucleas of the 
cell, with no cytoplasmic labeling. Its blue fluorescence stands out in vivid contrast to other 
fluorescence. DAPI can be excited with the following radiation sources: xenon, Hg-arc lamp 
and UV laser. Figure 4-12 displays its excitation-emission spectrum. Ex/Em is 358/461 nm. 
 




Figure 4-13 Single MCF-7 Cell Nucleus Stained with DAPI 
 
The procedure of labeling cells with DAPI is listed,  
1. Dilute the DAPI stock solution (14.3mM) to 300nM with PBS.  
2. Add 300 µl of this dilute DAPI staining solution to the cultured cells.  
3. Incubate for 1-5 minutes. 
 
A single MCF-7 cell nucleus stained with DAPI is displayed in Figure 4-13. 
4.3.2 Direct Immunofluorescence Assay with the CD45-PE 
Anti-CD45 conjugated with PE was purchased from BD Bioscience Pharmingen (San 
Diego, CA). It is an anti-human monoclonal antibody. It reacts with leukocyte common 
antigen (LCA) present on all human leukocytes including lymphocytes, monocytes, 
granulocytes, eosinophils and thymocytes. The CD45 PE will definitely stain human white 
blood cells but they should not stain the breast cancer tumor cell line. 




Figure 4-14 Excitation-Emission Spectra for (Phycoerythrin) PE (BD Bioscience, Palo Alto, 
California) 
 
The cells staining protocol with CD45-PE is proceeded as follows,  
1. Start by adding 40 µl of anti-CD45 PE to two million cultured cells and incubate 
for 30 minutes probably on ice in the dark. (Ratio of antibody to number of cells: 
20µl /106 cells). A tube of proper volume should be used for staining process. A 
bigger tube will be used for more cells.  
2. Wash the cell suspension with 1X Phosphate Buffer Solution (PBS) after the 30 
minutes incubation period. 
3. After the 30 minutes incubation period add the dual stained anti-CD45 PE / 
DAPI cell suspension to the micro-channel with syringe pump and view it 
immediately with the fluorescent microscope.  
4. Fine tune the assay with the right temperatures, times, etc.  
4.3.3 FITC-Cell Membrane Linker Labeling  
It was possible that DAPI debris or cell debris was present in the micro-channel. To 
ensure that the cells were intact and not ruptured or torn apart, lipid labeling was used to 




Figure 4-15  PKH 67 Excitation and Emission Spectra (Sigma, St. Louis, MO) 
 
A green fluorescent cell linker kit was obtained from Sigma (St. Louis, MO). It 
included PKH67 dye stock (1×10-3 M in ethanol) and diluent C.  This dye was used for cell 
membrane labeling. Diluent C was provided to maintain cell viability while maximizing 
staining efficiency. The Excitation / Emission is 490/502 nm.  
The protocol of labeling the cells with FITC-cell membrane linker was listed as 
follows,  
1. Centrifuge the cells at 400×g (1000 rpm) for 5 minutes into the loose pellet. 
2. After centrifuging the cells, decant supernatant and let the pellet stay on the 
bottom of the conical tube.  
3. Draw 10 µl of PKH 67 dye into the propylene tube, and dilute to 5×10-6 molar 
with 2 ml Diluent C.  
4. Rapidly add the 2 ml of staining solution to the cells and immediately mix the 
sample by gentle inverting the tube. Rapid and homogeneous mixing is the key 
for labeling due to the instantaneous staining.  
5. Incubate at 25°C for 4 minutes and constantly invert the tube gently to assure 
mixing well between the cells and PKH67 dye. 
6. Add 2ml of serum to stop the staining reaction. 
7. Dilute the serum-stopped sample with 10ml of tissue culture medium  
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8. Centrifuge the samples at 400×g (1000 rpm) for 10 minutes. Decant supernatant 
fluid and resuspend the cells with 2ml tissue culture medium. 
4.4 Flow System Experiment Set up 
After an anti-EpCAM functionalized micro-channel was prepared, the cultured cells 
were labeled with DAPI, anti-CD45-PE, and FITC cell membrane linker. A Programmable 
Pump 22, from Harvard Apparatus syringe pump, shown in Figure 4-17, was used to 
generate a constant flow velocity. There were two input parameters, the syringe diameter 
and volume flow rate. The syringe diameters varied for different companies, and had 
different minimum and maximum flow rates.  
Table 4-4 lists the minimum and maximum diameters available for Becton Dickinson 
plastic syringes of different volume.  
 
 
Figure 4-16  Cell Clusters Stained with DAPI and FITC 
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Figure 4-17 Harvard Apparatus Programmable Syringe Pump 22  
 
Table 4-4 Becton Dickinson Plastic Syringe Diameters, Minimum & Maximum Flow Rates 
Volume Size (cc) Diameter (mm) Minimum Flow Rate Maximum Flow Rate 
1 4.78 0.49 µl/min 805 µl/min 
3 8.66 0.011 ml/h 181.4 ml/h 
5 12.06 0.019 ml/h 317.0 ml/h 
10 14.50 0.028 ml/h 461.0 ml/h 
20 19.13 0.050 ml/h 821.0 ml/h 
30 21.70 0.074 ml/h 1208.0 ml/h 
50/60 26.70 0.002 ml/min 28.4 ml/min 
 
The inlet of the micro-channel and syringe output tip were connected using assembly 
components from Upchurch (Oak Harbor, WA), including tubing, luer adapters, a short 
headless nut, and a ferrule. The same outer diameter for all those components was required 
to get a tight connection, which was the key issue for cell line transport. The syringe was 
used to pump the cell-loaded solution through the tubing, and the micro-channels, which 




Figure 4-18  Experiment Setup 
4.5 Micro-Channel Generation and Cancer Cell Capture Evolution 
4.5.1 Cell Capture in 1st Micro-Channel Generation  
A mold insert and hot embossing micro-fabrication were used to produce PMMA 
micro-channels (50 µm (width) × 100 µm (height) × 5 cm (length)). This nickel mold insert 
was fabricated at the Center for Advance Microstructures and Devices (CAMD) and the hot 
embossing was done in the Chemistry Department. In the final PMMA micro-channel, two 
holes were drilled at the each end of long channel to serve as inlet and outlet respectively.  
 
 
        
Figure 4-19  Mold Insert Image of Micro-Channel (50µm×100µm×5cm) 
               




Figure 4-20  Micro-Channel without Anti-EpCAM Immobilization on Walls (50 µm × 100 
µm × 5 cm) 
 
Two microchips were prepared. One was PMMA micro-channel without surface 
modification and the other was a PMMA micro-channel with anti-EpCAM immobilized.  
Figure 4-20 shows a round MCF cell in the non-functionalized channel instead of 
being attached to the walls. Cells retained their round shapes, and there were no deformation 
of the cells in the micro-channel.  
Only three MCF-7 cells were captured at three different locations in micro-channel 
with the width of 50 µm (Figure 4-21). There were around a quarter of million cells flowed 
into the channel. These assured the breast cancer cells could be captured with the use of anti-
EpCAM modified micro-channel, but was not optimized to get high cell capture efficiency.  
After cells initially contacted the wall, they flattened and elongated, and became shaped like 
half an ellipse. The cell contact area radius was approximately 12 µm, which was also used 










Figure 4-22 Skipped Cells in Outlet Reservoir in 50 µm Width Micro-Channel 
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Cells that were not captured on the micro-channel wall and passed through the outlet 
reservoir (Figure 4-22). In a micro-channel larger than the cells, cells tended to flow in the 
central part of the channel and leave a cell-free layer along the channel wall. Cells had less 
chance to contact the channel wall. Therefore, in order to get high target cell capture 
efficiency, a narrow and deep micro-channel seemed to have the tendency to improve the 
capture efficiency.  
4.5.2 Cells Capture in 2nd Micro-Channel Generation 
When the micro-channel width was reduced, the cells had a much higher probability 
of encountering the micro-channel wall, rolling along the channel wall, and eventually 
adhering to the channel by the strong affinity between anti-EpCAM and EpCAM. However, 
if the channel is too narrow, the cells would block at the entrance. Austin reported that white 
blood cells stopped at the entrance of a channel instead of deforming into it (Austin, 1997). 
When a micro-channel’s width was the same magnitude as the cells, it would increase the 
surface contact area between the cells and channel wall. It was reasonable to increase the 
aspect ratio to further increase the surface contact area, and improve the cell capture 
efficiency. This idea tended out to be the correct guess. Once the cells got trapped on the 
channel, the bond strength was very strong. The flow velocity of 2mm/sec was much lower 
than the critical dissociation velocity predicted by the model. The captured cells remained 
anchored to the channel wall and would not strip away under the continuous flow.     
In Figure 4-24, a number of captured MCF cells are shown. Figure 4-25 demonstrates 
a global view of cell capture in the narrower micro-channel ((20µm×70µm×10cm) at a flow 
velocity of 2 mm/sec. Every where in the channel, the straight part, the curved channel, or 
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the edge of the outlet reservoir, the cancer cells were anchored to the channel wall. From 
that, reasonable coverage of anti-EpCAM antibody coated on the PMMA surface was 
assumed. Compared with Figure 4-22 taken in the reservoir location of the 50 µm micro-
channel, the reservoir in Figure 4-25 showed MCF-7 cells anchored only at the edge of 
outlet reservoir where the anti-EpCAM was immobilized. There were no skipped cancer 
cells staying in the reservoir. That displayed the high cell capture efficiency. In the picture 
of “Curved Channel Location”, the outer edge of the channel had more cancer cells captured 
due to the higher encounter rate compared with inner one. This phenomenon inspired 
consideration of the serpentine micro-channels in the future geometry for high capture cell 
efficiency and small footprint.  
The cell capture efficiency can be evaluated approximately by method of cell 
counting. The cell concentrations of the initial cells suspension and final cells solution can 
be evaluated with the use of a hemacytometer. The numbers of cells at those two stages are 
the products of cell concentration and cell suspension volume. Therefore, the capture 
efficiency is determined by the ratio of the number of cells staying in the micro-channel to 
the initial number of cells.   
    











Figure 4-25  Breast Cancer Cells Capture in Micro-Channel (20µm×70µm×10cm) at the 
Flow Velocity of 2mm/sec 
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4.5.3 3rd Micro-Channel Generation 
 
 
      
 
Figure 4-26 Mold Insert Image of Micro-Channel (50 µm × 120 µm × 5 cm) 
 
The cell-sorting micro-device should have high capture efficiency, quick processing 
times, and high throughput, so a parallel-multi micro-channel has been designed.  
 
 
                            Top View                                                 Side View 
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Chapter 5           Summary and Conclusions 
5.1 Summary of the Research Study 
Breast cancer, the most common cancer in women, represents the second leading 
cause of death in women in the United States. Early cancer detection is looked upon as an 
effective strategy to reduce the burden of this disease. A popular early breast cancer 
detection technique, screening mammography, cannot eliminate death from breast cancer 
because only highly calcified tumors that are ~1 mm in size can be detected and misses 
subsequent metastasis formation in other tissues. Also, mammogram screening brings about 
inconclusive results, which require patients to undergo other invasive and expensive follow-
up diagnostic procedures, such as the surgical biopsy, Fine Needle Aspiration (FNA), or 
Core Needle Biopsy (CNB) to determine if the tumors are malignant or benign.  
At the early stage of tumorigenesis, tumor cells shed into peripheral circulating blood, 
which in principle makes it possible to detect cancer cells in the blood stream before the 
primary tumor is large enough to be detected by standard screening techniques. In human 
blood, the only epithelial cells are tumor cells, so the EpCAM antigen over-expressed by 
breast cancer cells will be a precise precursor to detect breast cancer cells at the early stage 
of tumor growth and metastasis. 
The scale of the instrument available for diagnosis was reduced by using biochips and 
creating a Biological Micro-Electro-Mechanical Systems (Bio-MEMS) device to detect rare 
breast cancer cells in patients’ blood.  
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Antibody-antigen binding was used to detect and trap the target breast cancer cells 
from solution by designing a micro-device coated with anti-EpCAM antibodies.  
5.2 Summary of Results and Conclusions 
PMMA was chosen as the micro-device material due to its surface chemistry 
modification potential. Immobilization of anti-EpCAM antibodies was successfully done 
using a simple three-step protocol, introducing UV radiation, NH2-modification of PMMA, 
and antibody attachment to the PMMA. Immunofluorescent staining was used to test 
whether antibodies were immobilized or not. Direct staining using anti-EpCAM conjugated 
with FITC and indirect staining, with the use of pure anti-EpCAM, and a secondary 
antibody labeled with FITC were compared for evaluating immobilization performance. The 
indirect staining was adopted and recognized as the best way due to the large number of 
antibodies coated along the micro-channel increasing the target cell capture efficiency. 
Compared with the direct method, the indirect method did not obstruct the reaction between 
the antibodies and the NH2 group from fluorescein, and increased the density coverage of 
antibodies along the channel.  
Cancer cell detection in the transparent micro-channel was based on a multi-
fluorescence technique. Three fluorochromes, FITC (green), CD45-PE (red-orange), and 
DAPI (blue) were selected to differentiate the cancer cells from normal blood cells. Under 
fluorescence microscopy, breast cancer cells were identified by nuclei blue (DAPI positive), 
and green (FITC-cell membrane linker positive) lipid layers. White blood cells were 
identified by orange (CD45-PE positive), as well as having blue nuclei (DAPI positive) and 
green (FITC-cell membrane linker positive) lipid layers. With these three fluorochromes, 
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whether in the static case, with the target cancer cells anchored to the PMMA micro-channel 
or in the motile case with cancer cells rolling along the micro-channel, then binding to the 
surface and spreading in response to binding could be visualized under fluorescence 
microscopy.  
In simulations, Hammer’s model of the effect of flow velocity on receptor-ligand 
binding was adapted. In antibody-antigen binding under the flow field in the micro-channel, 
there were two competing mechanisms involved. With the increase in the flow velocity of 
the cancer cells, they encountered the anti-EpCAM-modified micro-channel more often, 
which increased the probability of generating an encounter complex. On the other hand, 
when the flow velocity increased, the encounter duration time decreased dramatically. Given 
insufficient encounter duration times, would the encounter complex would not form and 
ultimately lead to cell binding.  
In this non-dimensional model, the Peclet number (Pe) was introduced as a ratio of 
flow velocity, and 2-D convection-diffusion was used to obtain the relationship between the 
encounter rate and Pe. The probability of antibody-antigen binding was introduced to 
explain the relationship between the encounter duration time and Pe.  Combining those two 
factors, encounter rate and encounter duration time, an optimal velocity, at which the 
maximum numbers of Anti-EpCAM and EpCAM binding was determined to be 2mm/sec. 
This model could be applied in any specific receptor-ligand biosystem to get the optimal 
velocity.  
To calculate the binding strength between the captured cancer cells and PMMA micro-
channel, the Dembo binding affinity model and Bell kinetic model were used. Dembo 
speculated that the mechanical strength of adhesion varied with the logarithm of the binding 
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affinity of receptor/ligand bonds. Given the parameters, anti-EpCAM/EpCAM binding 
affinity, extent of bond stretch to reach critical force, the critical binding force for a single 
bond was determined. In the Bell kinetic model, at equilibrium, the critical force to break 
down one EpCAM-antiEpCAM bond was developed and the same result obtained. 
For contact area evaluation, the Cozens-Roberts model, which assumes that cell is a 
rigid and non-deformable sphere, yielded a surface contact area of 3.5 µm2. When the 
enlarged contact area due to the cell spreading response to binding was considered, the 
actual contact area was approximatly as 452 µm2. The estimated dissociation force 
integrated over the contact area after spreading was 0.48 dynes and the corresponding 
dissociation velocity was 10.6 m/s. The bond strength between the anti-EpCAM and 
EpCAM was very large once the cell spread, so it should be extremely difficult to uproot the 
cells from the surface.  
Three generations of micro-devices were used for cell capture. The first was a channel 
of width 50 µm × height 100 µm × length 5cm. Cells were pumped through both a non-
functionalized channel and an anti-EpCAM modified micro-channel. In the non-
functionalized channel, round MCF cells remained in the middle of the channel, and were 
not captured; however, in the treated channel, low numbers of cells were captured on the 
channel wall and most passed through to the outlet reservoir. Once the cells attached to the 
surface, they became flattened and elongated. The cell capture assured us that the anti-
EpCAM modified micro-channels would work, but the geometry had to be optimized to 
improve the cell capture probability. 
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To reduce the processing time and increase the high throughput, the 17 parallel micro-
channels (50 µm × 120 µm ×5 cm) were set up for further flow experiment.  
Therefore, in order to implement the separation of breast cancer cells from blood using 
the antibodies immobilized on the micro-channel wall, cells must be forced to contact the 
channel wall. Narrow and deep channels had been tested showing a good geometry because 
cells had more chances to contact the wall instead of staying in the middle part of the 
channel in the wider channel.  
Cell spreading on the antibodies-modified surface largely increase the bond force, 
therefore, larger flow velocity were required to wash the targeted cells off the surface. Also, 
in order to achieve flow the sample solution through the micro-channel in less than 10 
minutes, high throughput is necessary. Parallel multiplied micro-channels or annular 
geometries would be considered as potential channel geometries.  
The antibodies immobilization protocol can be applied for different designed 
geometries to coat the surface with a layer of antibodies and the cells detection with the use 
of fluorescence technology can also be applied to different designs.  
5.3 Areas of Future Research 
The selectivity of the micro-device is not determined yet. A mixture of white blood 
cells, red blood cells and MCF-7 cells will be used as the sample to test if the anti-EpCAM 
modified micro-channel will only recognize and collect the target cancer cells as expected.  
Cells may be run suspended in saline or other solution to improve capture rate. 
Removing the plasma from the blood through centrifugation and using normal saline would 
result in a less viscous suspension, so that the cells could be captured at faster rate. Altering 
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the salt concentration or lowering the temperature can sometimes increase the avidity of the 
antibody to enable the capture of cells in a faster flow. Experiments would need to be 
designed to evaluate these changes. A key issue is the improvement of the coverage of the 
antibodies along the micro-channel. To fully make use of the functionalized micro-channel, 
we may use the micro-pump assembled to this cell sorting micro-device to generate the 
repeated cycles. 
To reduce the processing time and increase the capture efficiency as well as the high 
throughput, various geometries of micro-devices will be designed and compared. Annular 
(Figure 5-1), serpentine (Figure 5-2), spiral (Figure 5-3), micro-posts and other geometries 
of the micro-devices will be laid out and incorporated into the microchip using a laser 
writing machine. In addition to the narrow and deep channels, other geometries, such as 
serpentine or annular channels utilizing the inertia forces to obtain more cells contact on the 
wall will be experimented. A computational model should be developed to compare the 
performance of cell capture with different geometries of micro-devices.  
 
Figure 5-1 Annular Micro-Device Geometry 
 
Figure 5-2 Serpentine Micro-Channel Geometry 
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Figure 5-3 Spiral Micro-Channel Geometry 
 
The future micro-devices would be coated with Molecular Imprinted Polymers (MIPs) 
monolayer instead of expensive antibody layer to catch the target cells. These MIPs are 
functionalized polymers, which can recognize and selectively bind guest EpCAM molecules 
because the shape and functionality of the guest has been "imprinted" during the 
polymerization. MIP is a promising new separation tool that has the potential of replacing 
antibodies in separations that demand high affinity and selectivity (Sellergren, 1997). Also, 
antibody-modified micro-device had to be stored in the dark and cold place. However, this 
future product, MIP coated microchip without any storage requirement would be more 
commercially popular as an early cancer detection device. The binding mechanism between 
MIP and molecules should be applied to get the dissociation force and the optimal velocity 
which guarantee the maximum bindings. 
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Appendix 1: Non Specific Force  















RAF chv  
where Ah is the Hamaker constant and χ is the constant on the order of h. 




















































where ρ  is the charge density of cell coats, Lc is the thickness of macromolecular 
layer on each surface, and κ is the reciprocal Debye-Huckel length. 
Steric Stabilization Force, Fs. 
For h > 2Lc 
0=sF  






hLRF −= λπ  
where ssλ is a phenomenological constant. 
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Parameter Definition value 
cR  Cell radius 12µm 
hA  Hamaker constant 5.0×10
-21J 
χ  Surface thickness 70Å 
cL  Cell coat thickness 10 nm 
1/κ  Debye-Huckel length 8Å 
ρ  Charge density 5.0C/cm3 
ε  Dielectric constant 7.08×10-19C2/(dyn⋅cm2) 






Appendix 2: Comparisons of Different Types of Applied Forces 
   
Assumptions: 

































ταθ 1                                                                                  
The geometry of this model also shows, 
)cos1(sin θφ −+= ahL                                             
Using the same assumption we made before, 2/1~sin 2αφ −  and 2/1~cos 2θθ − , the 
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Applying the definition of α  given as φα cos= , the relationship between shear force 
















αφ                          
Therefore, from the above derivation based on the mechanical force balance and 
geometry assumptions, the relationship between the shear force (F) and the tension of the 
bond (T) is obtained as shown in the above equation. Hence α , the ratio between F and T, is 
the determinant value to compare the shear force (tangential force) required for remove the 
attached cell from the surface to the normal force required for the detachment.  
When fluid flows through the micro-channel, the shear force is exerted on the cell 





Appendix 3: 3-D Velocity Distribution 
 

















































                                           
The figure below showed the 3-D velocity profile of blood in micro-channel with the 
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